array(1) { [0]=> object(Apache_Solr_Document)#24 (3) { ["_documentBoost":protected]=> bool(false) ["_fields":protected]=> array(6) { ["content_id"]=> array(1) { [0]=> string(14) "DIRECTORY_3799" } ["content_title"]=> array(1) { [0]=> string(13) "MARIO CAZZOLA" } ["description"]=> array(1) { [0]=> string(223715) " a:254:{i:0;a:14:{s:9:"citazione";s:328:"Calzetta, L., Ludovica Ritondo, B., de Marco, P., Cazzola, M., & Rogliani, P. (2021). Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile. EXPERT REVIEW OF RESPIRATORY MEDICINE, 15(4), 579-581 [10.1080/17476348.2021.1866835].";s:4:"data";s:4:"2021";s:2:"id";s:20:"PUBBLICAZIONE_432451";s:6:"handle";s:11:"2108/285484";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/10";s:9:"metadata4";N;s:9:"metadata5";s:154:"Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile";s:9:"metadata6";s:70:"Calzetta, L; Ludovica Ritondo, B; de Marco, P; Cazzola, M; Rogliani, P";s:9:"metadata7";s:29:"10.1080/17476348.2021.1866835";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:1;a:14:{s:9:"citazione";s:197:"Cazzola, M., Ora, J., Bianco, A., Rogliani, P., & Matera, M.G. (2021). Guidance on nebulization during the current COVID-19 pandemic. RESPIRATORY MEDICINE, 176, 106236 [10.1016/j.rmed.2020.106236].";s:4:"data";s:4:"2021";s:2:"id";s:20:"PUBBLICAZIONE_432446";s:6:"handle";s:11:"2108/285482";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/10";s:9:"metadata4";N;s:9:"metadata5";s:61:"Guidance on nebulization during the current COVID-19 pandemic";s:9:"metadata6";s:54:"Cazzola, M; Ora, J; Bianco, A; Rogliani, P; Matera, MG";s:9:"metadata7";s:26:"10.1016/j.rmed.2020.106236";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:2;a:14:{s:9:"citazione";s:230:"Rogliani, P., Ritondo, B.L., Ora, J., Cazzola, M., & Calzetta, L. (2020). SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. EUROPEAN RESPIRATORY JOURNAL, 56(3), 2000625 [10.1183/13993003.00625-2020].";s:4:"data";s:7:"2020-09";s:2:"id";s:20:"PUBBLICAZIONE_407090";s:6:"handle";s:11:"2108/262809";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/10";s:9:"metadata4";N;s:9:"metadata5";s:79:"SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis";s:9:"metadata6";s:57:"Rogliani, P; Ritondo, BL; Ora, J; Cazzola, M; Calzetta, L";s:9:"metadata7";s:27:"10.1183/13993003.00625-2020";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:3;a:14:{s:9:"citazione";s:205:"Calzetta, L., Matera, M.G., Rogliani, P., & Cazzola, M. (2020). The role of triple therapy in the management of COPD. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 13(8), 865-874 [10.1080/17512433.2020.1787830].";s:4:"data";s:7:"2020-08";s:2:"id";s:20:"PUBBLICAZIONE_407067";s:6:"handle";s:11:"2108/262791";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/10";s:9:"metadata4";N;s:9:"metadata5";s:52:"The role of triple therapy in the management of COPD";s:9:"metadata6";s:48:"Calzetta, L; Matera, MG; Rogliani, P; Cazzola, M";s:9:"metadata7";s:29:"10.1080/17512433.2020.1787830";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:4;a:14:{s:9:"citazione";s:168:"Cazzola, M., Stolz, D., Rogliani, P., & Matera, M.G. (2020). α1-Antitrypsin deficiency and chronic respiratory disorders. EUROPEAN RESPIRATORY REVIEW, 29(155), 190073.";s:4:"data";s:10:"2020-03-31";s:2:"id";s:20:"PUBBLICAZIONE_407064";s:6:"handle";s:11:"2108/262789";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/10";s:9:"metadata4";N;s:9:"metadata5";s:60:"α1-Antitrypsin deficiency and chronic respiratory disorders";s:9:"metadata6";s:45:"Cazzola, M; Stolz, D; Rogliani, P; Matera, MG";s:9:"metadata7";s:26:"10.1183/16000617.0073-2019";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:5;a:14:{s:9:"citazione";s:266:"Bernard, E., Nannya, Y., Hasserjian, R.P., Devlin, S.M., Tuechler, H., Medina-Martinez, J.S., et al. (2020). Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. NATURE MEDICINE, 26(10), 1549-1556.";s:4:"data";s:4:"2020";s:2:"id";s:20:"PUBBLICAZIONE_405901";s:6:"handle";s:11:"2108/261816";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/15";s:9:"metadata4";N;s:9:"metadata5";s:120:"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes";s:9:"metadata6";s:1005:"Bernard, E; Nannya, Y; Hasserjian, RP; Devlin, SM; Tuechler, H; Medina-Martinez, JS; Yoshizato, T; Shiozawa, Y; Saiki, R; Malcovati, L; Levine, MF; Arango, JE; Zhou, Y; Solé, F; Cargo, CA; Haase, D; Creignou, M; Germing, U; Zhang, Y; Gundem, G; Sarian, A; van de Loosdrecht, AA; Jädersten, M; Tobiasson, M; Kosmider, O; Follo, MY; Thol, F; Pinheiro, RF; Santini, V; Kotsianidis, I; Boultwood, J; Santos, FPS; Schanz, J; Kasahara, S; Ishikawa, T; Tsurumi, H; Takaori-Kondo, A; Kiguchi, T; Polprasert, C; Bennett, JM; Klimek, VM; Savona, MR; Belickova, M; Ganster, C; Palomo, L; Sanz, G; Ades, L; Della Porta, MG; Smith, AG; Werner, Y; Patel, M; Viale, A; Vanness, K; Neuberg, DS; Stevenson, KE; Menghrajani, K; Bolton, KL; Fenaux, P; Pellagatti, A; Platzbecker, U; Heuser, M; Valent, P; Chiba, S; Miyazaki, Y; Finelli, C; Voso, MT; Shih, L; Fontenay, M; Jansen, JH; Cervera, J; Atsuta, Y; Gattermann, N; Ebert, BL; Bejar, R; Greenberg, PL; Cazzola, M; Hellström-Lindberg, E; Ogawa, S; Papaemmanuil, E";s:9:"metadata7";s:25:"10.1038/s41591-020-1008-z";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:6;a:14:{s:9:"citazione";s:261:"Calzetta, L., Matera, M.G., Goldstein, M.F., Fairweather, W.R., Howard, W.W., Cazzola, M., et al. (2020). A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. PULMONARY PHARMACOLOGY & THERAPEUTICS, 60, 101883.";s:4:"data";s:4:"2020";s:2:"id";s:20:"PUBBLICAZIONE_407079";s:6:"handle";s:11:"2108/262799";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/10";s:9:"metadata4";N;s:9:"metadata5";s:103:"A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study";s:9:"metadata6";s:92:"Calzetta, L; Matera, MG; Goldstein, MF; Fairweather, WR; Howard, WW; Cazzola, M; Rogliani, P";s:9:"metadata7";s:26:"10.1016/j.pupt.2019.101883";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:7;a:14:{s:9:"citazione";s:252:"Cazzola, M., Rogliani, P., Calzetta, L., & Matera, M.G. (2020). Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy. PHARMACOGENOMICS AND PERSONALIZED MEDICINE, 13, 261-271 [10.2147/PGPM.S231471].";s:4:"data";s:4:"2020";s:2:"id";s:20:"PUBBLICAZIONE_407072";s:6:"handle";s:11:"2108/262795";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/10";s:9:"metadata4";N;s:9:"metadata5";s:107:"Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy";s:9:"metadata6";s:48:"Cazzola, M; Rogliani, P; Calzetta, L; Matera, MG";s:9:"metadata7";s:20:"10.2147/PGPM.S231471";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:8;a:14:{s:9:"citazione";s:200:"Matera, M.G., Page, C.P., Calzetta, L., Rogliani, P., & Cazzola, M. (2020). Pharmacology and Therapeutics of Bronchodilators Revisited. PHARMACOLOGICAL REVIEWS, 72(1), 218-252 [10.1124/pr.119.018150].";s:4:"data";s:4:"2020";s:2:"id";s:20:"PUBBLICAZIONE_407044";s:6:"handle";s:11:"2108/262768";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/10";s:9:"metadata4";N;s:9:"metadata5";s:58:"Pharmacology and Therapeutics of Bronchodilators Revisited";s:9:"metadata6";s:58:"Matera, MG; Page, CP; Calzetta, L; Rogliani, P; Cazzola, M";s:9:"metadata7";s:21:"10.1124/pr.119.018150";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:9;a:14:{s:9:"citazione";s:234:"Matera, M.G., Rogliani, P., Bianco, A., & Cazzola, M. (2020). Pharmacological management of adult patients with acute respiratory distress syndrome. EXPERT OPINION ON PHARMACOTHERAPY, 21(17), 2169-2183 [10.1080/14656566.2020.1801636].";s:4:"data";s:4:"2020";s:2:"id";s:20:"PUBBLICAZIONE_407070";s:6:"handle";s:11:"2108/262793";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/10";s:9:"metadata4";N;s:9:"metadata5";s:85:"Pharmacological management of adult patients with acute respiratory distress syndrome";s:9:"metadata6";s:46:"Matera, MG; Rogliani, P; Bianco, A; Cazzola, M";s:9:"metadata7";s:29:"10.1080/14656566.2020.1801636";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:10;a:14:{s:9:"citazione";s:313:"Rogliani, P., Matera, M.G., Facciolo, F., Page, C., Cazzola, M., & Calzetta, L. (2020). Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo. BRITISH JOURNAL OF PHARMACOLOGY, 177(5), 1150-1163 [10.1111/bph.14909].";s:4:"data";s:4:"2020";s:2:"id";s:20:"PUBBLICAZIONE_407081";s:6:"handle";s:11:"2108/262803";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/10";s:9:"metadata4";N;s:9:"metadata5";s:152:"Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo";s:9:"metadata6";s:70:"Rogliani, P; Matera, MG; Facciolo, F; Page, C; Cazzola, M; Calzetta, L";s:9:"metadata7";s:17:"10.1111/bph.14909";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:11;a:14:{s:9:"citazione";s:280:"Rogliani, P., Ritondo, B.L., Zerillo, B., Cazzola, M., Matera, M.G., & Calzetta, L. (2020). Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination. COPD, 17(2), 215-223.";s:4:"data";s:4:"2020";s:2:"id";s:20:"PUBBLICAZIONE_407085";s:6:"handle";s:11:"2108/262805";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/10";s:9:"metadata4";N;s:9:"metadata5";s:165:"Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination";s:9:"metadata6";s:73:"Rogliani, P; Ritondo, BL; Zerillo, B; Cazzola, M; Matera, MG; Calzetta, L";s:9:"metadata7";s:29:"10.1080/15412555.2020.1749252";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:12;a:14:{s:9:"citazione";s:170:"Cazzola, M., Rogliani, P., & Matera, M.G. (2019). The future of bronchodilation: looking for new classes of bronchodilators. EUROPEAN RESPIRATORY REVIEW, 28(154), 190095.";s:4:"data";s:10:"2019-12-31";s:2:"id";s:20:"PUBBLICAZIONE_406965";s:6:"handle";s:11:"2108/262690";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/10";s:9:"metadata4";N;s:9:"metadata5";s:73:"The future of bronchodilation: looking for new classes of bronchodilators";s:9:"metadata6";s:35:"Cazzola, M; Rogliani, P; Matera, MG";s:9:"metadata7";s:26:"10.1183/16000617.0095-2019";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:13;a:14:{s:9:"citazione";s:207:"Calzetta, L., Cazzola, M., Matera, M.G., & Rogliani, P. (2019). Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple combination therapy in COPD. CHEST, 155(4), 758-770 [10.1016/j.chest.2018.12.016].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_355209";s:6:"handle";s:11:"2108/217784";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:88:"Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple combination therapy in COPD";s:9:"metadata6";s:48:"Calzetta, L; Cazzola, M; Matera, MG; Rogliani, P";s:9:"metadata7";s:27:"10.1016/j.chest.2018.12.016";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:14;a:14:{s:9:"citazione";s:129:"Calzetta, L., Cazzola, M., Matera, M.g., & Rogliani, P. (2019). Response. CHEST, 155(5), 1079-1080 [10.1016/j.chest.2019.01.028].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_355217";s:6:"handle";s:11:"2108/217792";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:8:"Response";s:9:"metadata6";s:48:"Calzetta, L; Cazzola, M; Matera, Mg; Rogliani, P";s:9:"metadata7";s:27:"10.1016/j.chest.2019.01.028";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:15;a:14:{s:9:"citazione";s:284:"Calzetta, L., Di Marco, F., Blasi, F., Cazzola, M., Centanni, S., Micheletto, C., et al. (2019). Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. PULMONARY PHARMACOLOGY & THERAPEUTICS, 59, 101855 [10.1016/j.pupt.2019.101855].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_360944";s:6:"handle";s:11:"2108/222245";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:106:"Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis";s:9:"metadata6";s:97:"Calzetta, L; Di Marco, F; Blasi, F; Cazzola, M; Centanni, S; Micheletto, C; Rossi, A; Rogliani, P";s:9:"metadata7";s:26:"10.1016/j.pupt.2019.101855";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:16;a:14:{s:9:"citazione";s:197:"Calzetta, L., Gabriella Matera, M., Rogliani, P., & Cazzola, M. (2019). Dual phosphodiesterase PDE3/4 inhibitor Treatment of COPD Treatment of cystic fibrosis. DRUGS OF THE FUTURE, 44(11), 845-854.";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_406943";s:6:"handle";s:11:"2108/262684";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/10";s:9:"metadata4";N;s:9:"metadata5";s:86:"Dual phosphodiesterase PDE3/4 inhibitor Treatment of COPD Treatment of cystic fibrosis";s:9:"metadata6";s:57:"Calzetta, L; Gabriella Matera, M; Rogliani, P; Cazzola, M";s:9:"metadata7";s:30:"10.1358/dof.2019.44.11.3068792";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:17;a:14:{s:9:"citazione";s:222:"Calzetta, L., Matera, M.G., Cazzola, M., & Rogliani, P. (2019). Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. ADVANCES IN THERAPY, 36(12), 3291-3298.";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_406963";s:6:"handle";s:11:"2108/262688";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/10";s:9:"metadata4";N;s:9:"metadata5";s:117:"Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients";s:9:"metadata6";s:48:"Calzetta, L; Matera, MG; Cazzola, M; Rogliani, P";s:9:"metadata7";s:26:"10.1007/s12325-019-01119-w";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:18;a:14:{s:9:"citazione";s:295:"Calzetta, L., Rogliani, P., Page, C., Rinaldi, B., Cazzola, M., & Matera, M.g. (2019). Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. PULMONARY PHARMACOLOGY & THERAPEUTICS, 56, 39-50 [10.1016/j.pupt.2019.03.004].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_355224";s:6:"handle";s:11:"2108/217800";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:128:"Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways";s:9:"metadata6";s:69:"Calzetta, L; Rogliani, P; Page, C; Rinaldi, B; Cazzola, M; Matera, Mg";s:9:"metadata7";s:26:"10.1016/j.pupt.2019.03.004";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:19;a:14:{s:9:"citazione";s:222:"Cazzola, M., Calzetta, L., Page, C., Rogliani, P., & Matera, M.g. (2019). Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. TRENDS IN PHARMACOLOGICAL SCIENCES, 40(7), 452-463 [10.1016/j.tips.2019.04.015].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_355241";s:6:"handle";s:11:"2108/217809";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:66:"Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics";s:9:"metadata6";s:57:"Cazzola, M; Calzetta, L; Page, C; Rogliani, P; Matera, Mg";s:9:"metadata7";s:26:"10.1016/j.tips.2019.04.015";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:20;a:14:{s:9:"citazione";s:239:"Cazzola, M., Calzetta, L., Rogliani, P., & Matera, M.g. (2019). Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 28(10), 827-833 [10.1080/13543784.2019.1661990].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_360932";s:6:"handle";s:11:"2108/222233";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:84:"Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD";s:9:"metadata6";s:48:"Cazzola, M; Calzetta, L; Rogliani, P; Matera, Mg";s:9:"metadata7";s:29:"10.1080/13543784.2019.1661990";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:21;a:14:{s:9:"citazione";s:208:"Cazzola, M., Puxeddu, E., Matera, M.g., & Rogliani, P. (2019). A potential role of triple therapy for asthma patients. EXPERT REVIEW OF RESPIRATORY MEDICINE, 13(11), 1079-1085 [10.1080/17476348.2019.1657408].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_360936";s:6:"handle";s:11:"2108/222237";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:54:"A potential role of triple therapy for asthma patients";s:9:"metadata6";s:47:"Cazzola, M; Puxeddu, E; Matera, Mg; Rogliani, P";s:9:"metadata7";s:29:"10.1080/17476348.2019.1657408";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:22;a:14:{s:9:"citazione";s:153:"Cazzola, M., Rogliani, P., & Matera, M.g. (2019). Ultra-LABAs for the treatment of asthma. RESPIRATORY MEDICINE, 156, 47-52 [10.1016/j.rmed.2019.08.005].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_356920";s:6:"handle";s:11:"2108/219134";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:39:"Ultra-LABAs for the treatment of asthma";s:9:"metadata6";s:35:"Cazzola, M; Rogliani, P; Matera, Mg";s:9:"metadata7";s:26:"10.1016/j.rmed.2019.08.005";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:23;a:14:{s:9:"citazione";s:189:"Cazzola, M., Rogliani, P., Calzetta, L., & Matera, M.g. (2019). Bronchodilators in subjects with asthma-related comorbidities. RESPIRATORY MEDICINE, 151, 43-48 [10.1016/j.rmed.2019.04.001].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_355215";s:6:"handle";s:11:"2108/217790";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:61:"Bronchodilators in subjects with asthma-related comorbidities";s:9:"metadata6";s:48:"Cazzola, M; Rogliani, P; Calzetta, L; Matera, Mg";s:9:"metadata7";s:26:"10.1016/j.rmed.2019.04.001";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:24;a:14:{s:9:"citazione";s:145:"Cazzola, M., Rogliani, P., Stolz, D., & Matera, M.G. (2019). Pharmacological treatment and current controversies in COPD. F1000RESEARCH, 8, 1533.";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_406941";s:6:"handle";s:11:"2108/262682";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/10";s:9:"metadata4";N;s:9:"metadata5";s:59:"Pharmacological treatment and current controversies in COPD";s:9:"metadata6";s:45:"Cazzola, M; Rogliani, P; Stolz, D; Matera, MG";s:9:"metadata7";s:30:"10.12688/f1000research.19811.1";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:25;a:14:{s:9:"citazione";s:192:"Matera, M.g., Calzetta, L., Rogliani, P., & Cazzola, M. (2019). Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. RESPIRATORY MEDICINE, 153, 3-13 [10.1016/j.rmed.2019.05.005].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_355243";s:6:"handle";s:11:"2108/217811";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:65:"Monoclonal antibodies for severe asthma: Pharmacokinetic profiles";s:9:"metadata6";s:48:"Matera, Mg; Calzetta, L; Rogliani, P; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.rmed.2019.05.005";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:26;a:14:{s:9:"citazione";s:243:"Matera, M.g., Rinaldi, B., Calzetta, L., Rogliani, P., & Cazzola, M. (2019). Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. PULMONARY PHARMACOLOGY & THERAPEUTICS, 58, 101828 [10.1016/j.pupt.2019.101828].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_356922";s:6:"handle";s:11:"2108/219136";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:85:"Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment";s:9:"metadata6";s:60:"Matera, Mg; Rinaldi, B; Calzetta, L; Rogliani, P; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.pupt.2019.101828";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:27;a:14:{s:9:"citazione";s:280:"Rogliani, P., Calzetta, L., Matera, M.g., di Daniele, N., Girolami, A., Cazzola, M., et al. (2019). Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 20(6), 737-750 [10.1080/14656566.2019.1570133].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_355211";s:6:"handle";s:11:"2108/217786";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:96:"Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease";s:9:"metadata6";s:84:"Rogliani, P; Calzetta, L; Matera, Mg; di Daniele, N; Girolami, A; Cazzola, M; Ora, J";s:9:"metadata7";s:29:"10.1080/14656566.2019.1570133";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:28;a:14:{s:9:"citazione";s:243:"Rogliani, P., Calzetta, L., Ora, J., Cazzola, M., & Matera, M.g. (2019). Efficacy and safety profile of doxofylline compared to theophylline in asthma: A meta-analysis. MULTIDISCIPLINARY RESPIRATORY MEDICINE, 14(1) [10.1186/s40248-019-0189-0].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_356916";s:6:"handle";s:11:"2108/219130";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:48:"Asthma; Doxofylline; Theophylline; Meta-analysis";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:94:"Efficacy and safety profile of doxofylline compared to theophylline in asthma: A meta-analysis";s:9:"metadata6";s:56:"Rogliani, P; Calzetta, L; Ora, J; Cazzola, M; Matera, Mg";s:9:"metadata7";s:25:"10.1186/s40248-019-0189-0";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:29;a:14:{s:9:"citazione";s:212:"Rogliani, P., Cazzola, M., & Calzetta, L. (2019). Cardiovascular Disease in Chronic Respiratory Disorders and Beyond. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 73(17), 2178-2180 [10.1016/j.jacc.2018.11.068].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_355219";s:6:"handle";s:11:"2108/217794";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:66:"Cardiovascular Disease in Chronic Respiratory Disorders and Beyond";s:9:"metadata6";s:36:"Rogliani, P; Cazzola, M; Calzetta, L";s:9:"metadata7";s:26:"10.1016/j.jacc.2018.11.068";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:30;a:14:{s:9:"citazione";s:324:"Rogliani, P., Matera, M.G., Page, C., Puxeddu, E., Cazzola, M., & Calzetta, L. (2019). Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. RESPIRATORY RESEARCH, 20(1) [10.1186/s12931-019-1078-y].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_355221";s:6:"handle";s:11:"2108/217796";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:179:"Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine";s:9:"metadata6";s:69:"Rogliani, P; Matera, MG; Page, C; Puxeddu, E; Cazzola, M; Calzetta, L";s:9:"metadata7";s:25:"10.1186/s12931-019-1078-y";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:31;a:14:{s:9:"citazione";s:257:"Rogliani, P., Matera, M.g., Calzetta, L., Hanania, N.a., Page, C., Rossi, I., et al. (2019). Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. RESPIRATORY MEDICINE, 154, 86-92 [10.1016/j.rmed.2019.06.015].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_355230";s:6:"handle";s:11:"2108/217804";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:100:"Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients";s:9:"metadata6";s:125:"Rogliani, P; Matera, Mg; Calzetta, L; Hanania, Na; Page, C; Rossi, I; Andreadi, A; Galli, A; Coppola, A; Cazzola, M; Lauro, D";s:9:"metadata7";s:26:"10.1016/j.rmed.2019.06.015";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:32;a:14:{s:9:"citazione";s:363:"Rogliani, P., Matera, M.g., Ritondo, B.l., De Guido, I., Puxeddu, E., Cazzola, M., et al. (2019). Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. PULMONARY PHARMACOLOGY & THERAPEUTICS, 59, 101841 [10.1016/j.pupt.2019.101841].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_360946";s:6:"handle";s:11:"2108/222247";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:184:"Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations";s:9:"metadata6";s:86:"Rogliani, P; Matera, Mg; Ritondo, Bl; De Guido, I; Puxeddu, E; Cazzola, M; Calzetta, L";s:9:"metadata7";s:26:"10.1016/j.pupt.2019.101841";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:33;a:14:{s:9:"citazione";s:303:"Sposato, B., Scalese, M., Milanese, M., Masieri, S., Cavaliere, C., Latorre, M., et al. (2019). Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE, 7(5), 1643-1646 [10.1016/j.jaip.2019.03.006].";s:4:"data";s:4:"2019";s:2:"id";s:20:"PUBBLICAZIONE_355213";s:6:"handle";s:11:"2108/217788";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:103:"Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes";s:9:"metadata6";s:223:"Sposato, B; Scalese, M; Milanese, M; Masieri, S; Cavaliere, C; Latorre, M; Scichilone, N; Ricci, A; Cresti, A; Santus, P; Olivieri, C; Perrella, A; Rogliani, P; Paggiaro, P; Omalizumab Italian Study, G; Cazzola, M; Scala, R";s:9:"metadata7";s:26:"10.1016/j.jaip.2019.03.006";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:34;a:14:{s:9:"citazione";s:218:"Cazzola, M., Matera, M.g., Levi-Schaffer, F., & Rogliani, P. (2018). Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. EXPERT OPINION ON DRUG SAFETY [10.1080/14740338.2018.1446940].";s:4:"data";s:10:"2018-02-27";s:2:"id";s:20:"PUBBLICAZIONE_327223";s:6:"handle";s:11:"2108/194904";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:85:"Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab";s:9:"metadata6";s:53:"Cazzola, M; Matera, Mg; Levi-Schaffer, F; Rogliani, P";s:9:"metadata7";s:29:"10.1080/14740338.2018.1446940";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:35;a:14:{s:9:"citazione";s:296:"Cazzola, M., Rogliani, P., & Matera, M.g. (2018). Long‑term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved. POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 128(1), 895-897-897 [10.20452/pamw.4197].";s:4:"data";s:10:"2018-01-31";s:2:"id";s:20:"PUBBLICAZIONE_325324";s:6:"handle";s:11:"2108/193286";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:164:"Long‑term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved";s:9:"metadata6";s:35:"Cazzola, M; Rogliani, P; Matera, Mg";s:9:"metadata7";s:18:"10.20452/pamw.4197";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:36;a:14:{s:9:"citazione";s:268:"Calzetta, L., Matera, M.G., Facciolo, F., Cazzola, M., & Rogliani, P. (2018). Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. RESPIRATORY RESEARCH, 19(1), 65 [10.1186/s12931-018-0770-7].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_330499";s:6:"handle";s:11:"2108/197723";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:128:"Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways";s:9:"metadata6";s:61:"Calzetta, L; Matera, MG; Facciolo, F; Cazzola, M; Rogliani, P";s:9:"metadata7";s:25:"10.1186/s12931-018-0770-7";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:37;a:14:{s:9:"citazione";s:243:"Calzetta, L., Matera, M.g., Rogliani, P., & Cazzola, M. (2018). Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. EXPERT REVIEW OF RESPIRATORY MEDICINE, 12(4), 261-264 [10.1080/17476348.2018.1442216].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_327218";s:6:"handle";s:11:"2108/194898";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:91:"Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how";s:9:"metadata6";s:48:"Calzetta, L; Matera, Mg; Rogliani, P; Cazzola, M";s:9:"metadata7";s:29:"10.1080/17476348.2018.1442216";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:38;a:14:{s:9:"citazione";s:237:"Calzetta, L., Matera, M.g., Rogliani, P., & Cazzola, M. (2018). Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. EXPERT REVIEW OF RESPIRATORY MEDICINE, 12(8), 693-708 [10.1080/17476348.2018.1495562].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_344579";s:6:"handle";s:11:"2108/209542";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:85:"Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease";s:9:"metadata6";s:48:"Calzetta, L; Matera, Mg; Rogliani, P; Cazzola, M";s:9:"metadata7";s:29:"10.1080/17476348.2018.1495562";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:39;a:14:{s:9:"citazione";s:289:"Calzetta, L., Rogliani, P., Facciolo, F., Rinaldi, B., Cazzola, M., & Matera, M.g. (2018). N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. BIOMÉDECINE & PHARMACOTHÉRAPIE, 103, 1-8 [10.1016/j.biopha.2018.04.011].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_344511";s:6:"handle";s:11:"2108/209476";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:122:"N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation";s:9:"metadata6";s:73:"Calzetta, L; Rogliani, P; Facciolo, F; Rinaldi, B; Cazzola, M; Matera, Mg";s:9:"metadata7";s:28:"10.1016/j.biopha.2018.04.011";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:40;a:14:{s:9:"citazione";s:203:"Cazzola, M., & Rogliani, P. (2018). Tiotropium could provide benefits in the early stage of COPD, but further studies are needed. BMJ EVIDENCE-BASED MEDICINE, 23(5), 183-184 [10.1136/bmjebm-2018-110940].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_344597";s:6:"handle";s:11:"2108/209554";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:92:"Tiotropium could provide benefits in the early stage of COPD, but further studies are needed";s:9:"metadata6";s:23:"Cazzola, M; Rogliani, P";s:9:"metadata7";s:26:"10.1136/bmjebm-2018-110940";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:41;a:14:{s:9:"citazione";s:255:"Cazzola, M., Calzetta, L., Matera, M.g., Hanania, N.a., & Rogliani, P. (2018). How does race/ethnicity influence pharmacological response to asthma therapies?. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 14(4), 435-446 [10.1080/17425255.2018.1449833].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_344525";s:6:"handle";s:11:"2108/209491";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:79:"How does race/ethnicity influence pharmacological response to asthma therapies?";s:9:"metadata6";s:61:"Cazzola, M; Calzetta, L; Matera, Mg; Hanania, Na; Rogliani, P";s:9:"metadata7";s:29:"10.1080/17425255.2018.1449833";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:42;a:14:{s:9:"citazione";s:224:"Cazzola, M., Calzetta, L., Page, C., Rogliani, P., & Matera, M.g. (2018). Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. PULMONARY PHARMACOLOGY & THERAPEUTICS, 48, 185-194 [10.1016/j.pupt.2017.11.009].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_323803";s:6:"handle";s:11:"2108/192008";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:68:"Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis";s:9:"metadata6";s:57:"Cazzola, M; Calzetta, L; Page, C; Rogliani, P; Matera, Mg";s:9:"metadata7";s:26:"10.1016/j.pupt.2017.11.009";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:43;a:14:{s:9:"citazione";s:207:"Cazzola, M., Calzetta, L., Rogliani, P., Page, C., & Matera, M.g. (2018). Impact of doxofylline in COPD: A pairwise meta-analysis. PULMONARY PHARMACOLOGY & THERAPEUTICS, 51, 1-9 [10.1016/j.pupt.2018.04.010].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_344518";s:6:"handle";s:11:"2108/209484";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:55:"Impact of doxofylline in COPD: A pairwise meta-analysis";s:9:"metadata6";s:57:"Cazzola, M; Calzetta, L; Rogliani, P; Page, C; Matera, Mg";s:9:"metadata7";s:26:"10.1016/j.pupt.2018.04.010";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:44;a:14:{s:9:"citazione";s:237:"Cazzola, M., Matera, M.g., Rogliani, P., & Calzetta, L. (2018). Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 27(7), 573-581 [10.1080/13543784.2018.1492548].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_344516";s:6:"handle";s:11:"2108/209481";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:83:"Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?";s:9:"metadata6";s:48:"Cazzola, M; Matera, Mg; Rogliani, P; Calzetta, L";s:9:"metadata7";s:29:"10.1080/13543784.2018.1492548";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:45;a:14:{s:9:"citazione";s:221:"Cazzola, M., Rogliani, P., Calzetta, L., & Matera, M.G. (2018). Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. EUROPEAN RESPIRATORY JOURNAL, 52(6).";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_344605";s:6:"handle";s:11:"2108/209562";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:119:"Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis";s:9:"metadata6";s:48:"Cazzola, M; Rogliani, P; Calzetta, L; Matera, MG";s:9:"metadata7";s:27:"10.1183/13993003.01586-2018";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:46;a:14:{s:9:"citazione";s:280:"Cazzola, M., Rogliani, P., Puxeddu, E., Ora, J., & Matera, M.g. (2018). An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?. EXPERT REVIEW OF RESPIRATORY MEDICINE, 12(1), 43-54 [10.1080/17476348.2018.1398086].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_323801";s:6:"handle";s:11:"2108/192006";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:122:"An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?";s:9:"metadata6";s:55:"Cazzola, M; Rogliani, P; Puxeddu, E; Ora, J; Matera, Mg";s:9:"metadata7";s:29:"10.1080/17476348.2018.1398086";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:47;a:14:{s:9:"citazione";s:244:"Mantero, M., Rogliani, P., Cazzola, M., Blasi, F., & Di Pasquale, M. (2018). Emerging antibacterial and antiviral drugs for treating respiratory tract infections. EXPERT OPINION ON EMERGING DRUGS, 23(3), 185-199 [10.1080/14728214.2018.1504020].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_344513";s:6:"handle";s:11:"2108/209479";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:84:"Emerging antibacterial and antiviral drugs for treating respiratory tract infections";s:9:"metadata6";s:61:"Mantero, M; Rogliani, P; Cazzola, M; Blasi, F; Di Pasquale, M";s:9:"metadata7";s:29:"10.1080/14728214.2018.1504020";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:48;a:14:{s:9:"citazione";s:302:"Matera, M.g., Calzetta, L., Gritti, G., Gallo, L., Perfetto, B., Donnarumma, G., et al. (2018). Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. EUROPEAN JOURNAL OF PHARMACOLOGY, 832, 114-119 [10.1016/j.ejphar.2018.05.023].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_344583";s:6:"handle";s:11:"2108/209544";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:126:"Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells";s:9:"metadata6";s:123:"Matera, Mg; Calzetta, L; Gritti, G; Gallo, L; Perfetto, B; Donnarumma, G; Cazzola, M; Rogliani, P; Donniacuo, M; Rinaldi, B";s:9:"metadata7";s:28:"10.1016/j.ejphar.2018.05.023";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:49;a:14:{s:9:"citazione";s:299:"Matera, M.g., Rinaldi, B., Page, C., Rogliani, P., & Cazzola, M. (2018). Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 14(10), 1101-1111 [10.1080/17425255.2018.1530215].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_344599";s:6:"handle";s:11:"2108/209556";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:126:"Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease";s:9:"metadata6";s:56:"Matera, Mg; Rinaldi, B; Page, C; Rogliani, P; Cazzola, M";s:9:"metadata7";s:29:"10.1080/17425255.2018.1530215";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:50;a:14:{s:9:"citazione";s:224:"Matera, M.g., Rogliani, P., Calzetta, L., & Cazzola, M. (2018). Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 14(2), 239-245 [10.1080/17425255.2018.1421170].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_325318";s:6:"handle";s:11:"2108/193280";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:63:"Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma";s:9:"metadata6";s:48:"Matera, Mg; Rogliani, P; Calzetta, L; Cazzola, M";s:9:"metadata7";s:29:"10.1080/17425255.2018.1421170";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:51;a:14:{s:9:"citazione";s:267:"Matera, M.g., Rogliani, P., Ora, J., & Cazzola, M. (2018). Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. EXPERT OPINION ON PHARMACOTHERAPY, 19(18), 2043-2053 [10.1080/14656566.2018.1534957].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_344609";s:6:"handle";s:11:"2108/209566";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:121:"Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents";s:9:"metadata6";s:43:"Matera, Mg; Rogliani, P; Ora, J; Cazzola, M";s:9:"metadata7";s:29:"10.1080/14656566.2018.1534957";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:52;a:14:{s:9:"citazione";s:180:"Rogliani, P., Calzetta, L., & Cazzola, M. (2018). Is ICS–LAMA an alternative option to treat patients with COPD?. THE LANCET RESPIRATORY MEDICINE [10.1016/S2213-2600(18)30139-5].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_330385";s:6:"handle";s:11:"2108/197608";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:64:"Is ICS–LAMA an alternative option to treat patients with COPD?";s:9:"metadata6";s:36:"Rogliani, P; Calzetta, L; Cazzola, M";s:9:"metadata7";s:29:"10.1016/S2213-2600(18)30139-5";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:53;a:14:{s:9:"citazione";s:237:"Rogliani, P., Calzetta, L., Braido, F., Cazzola, M., Clini, E., Pelaia, G., et al. (2018). LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. INTERNATIONAL JOURNAL OF COPD, 13, 3115-3130 [10.2147/COPD.S170606].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_344504";s:6:"handle";s:11:"2108/209469";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:76:"LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review";s:9:"metadata6";s:106:"Rogliani, P; Calzetta, L; Braido, F; Cazzola, M; Clini, E; Pelaia, G; Rossi, A; Scichilone, N; Di Marco, F";s:9:"metadata7";s:20:"10.2147/COPD.S170606";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:54;a:14:{s:9:"citazione";s:291:"Rogliani, P., Matera, M.g., Puxeddu, E., Mantero, M., Blasi, F., Cazzola, M., et al. (2018). Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. PULMONARY PHARMACOLOGY & THERAPEUTICS, 50, 28-37 [10.1016/j.pupt.2018.03.004].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_330380";s:6:"handle";s:11:"2108/197604";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:118:"Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis";s:9:"metadata6";s:82:"Rogliani, P; Matera, Mg; Puxeddu, E; Mantero, M; Blasi, F; Cazzola, M; Calzetta, L";s:9:"metadata7";s:26:"10.1016/j.pupt.2018.03.004";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:55;a:14:{s:9:"citazione";s:236:"Rogliani, P., Ora, J., Matera, M.g., Cazzola, M., & Calzetta, L. (2018). The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. EXPERT OPINION ON DRUG SAFETY, 17(6), 589-596 [10.1080/14740338.2018.1472232].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_344508";s:6:"handle";s:11:"2108/209474";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:83:"The safety of dual bronchodilation on cardiovascular serious adverse events in COPD";s:9:"metadata6";s:56:"Rogliani, P; Ora, J; Matera, Mg; Cazzola, M; Calzetta, L";s:9:"metadata7";s:29:"10.1080/14740338.2018.1472232";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:56;a:14:{s:9:"citazione";s:316:"Rogliani, P., Ora, J., Puxeddu, E., Calzetta, L., Cavalli, F., Matera, M.g., et al. (2018). Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. PULMONARY PHARMACOLOGY & THERAPEUTICS, 49, 20-26 [10.1016/j.pupt.2017.12.010].";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_330382";s:6:"handle";s:11:"2108/197606";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:144:"Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study";s:9:"metadata6";s:80:"Rogliani, P; Ora, J; Puxeddu, E; Calzetta, L; Cavalli, F; Matera, Mg; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.pupt.2017.12.010";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:57;a:14:{s:9:"citazione";s:243:"Cazzola, M., Rogliani, P., Aliberti, S., Blasi, F., & Matera, M. (2017). An update on the pharmacotherapeutic management of lower respiratory tract infections. EXPERT OPINION ON PHARMACOTHERAPY, 18(10), 973-988 [10.1080/14656566.2017.1328497].";s:4:"data";s:10:"2017-05-06";s:2:"id";s:20:"PUBBLICAZIONE_312081";s:6:"handle";s:11:"2108/181384";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:211:"Adjuvant therapies; COPD exacerbation; antibiotic regimen; biomarkers; bronchiectasis; community-acquired pneumonia; guidelines; hospital acquired pneumonia; lower respiratory tract infections; novel antibiotics";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";s:1421:"Our knowledge about lower respiratory tract infections (LRTIs) has improved substantially in the last years, but the management of respiratory infections is still a challenge and we are still far from precision medicine in the treatment of LRTIs. Areas covered: The approaches developed in recent years to improve the pharmacotherapeutic management of LRTIs, such as novel diagnostic assays to facilitate medical decision-making, attempts for selecting an optimal empiric antibiotic regimen, and the role of new and possibly unproven adjunctive therapies, are described. Expert opinion: Early and appropriate antibiotics remain the cornerstone in the treatment of LRTIs. The updated trend is to apply antimicrobial stewardship principles and initiatives to optimize both the management and the outcomes of LTRIs. Biomarkers, mainly C-reactive protein (CRP) and procalcitonin (PCT), can improve the diagnostic and prognostic assessment of LRTIs and aid to guide antibiotic therapy. The widespread use of antimicrobial agents has greatly contributed to faster development of antibiotic resistance and the emergence of opportunistic pathogens, which substitute the indigenous microbiota. However, very few new antibiotics in development to overcome existing resistance and ensure continued success in the treatment of LRTIs have been approved, likely because antibiotic stewardship programs discourage the use of new agents.";s:9:"metadata5";s:85:"An update on the pharmacotherapeutic management of lower respiratory tract infections";s:9:"metadata6";s:57:"Cazzola, M; Rogliani, P; Aliberti, S; Blasi, F; Matera, M";s:9:"metadata7";s:29:"10.1080/14656566.2017.1328497";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:58;a:14:{s:9:"citazione";s:237:"CALZETTA, L., Matera, M., Braido, F., Contoli, M., Corsico, A., Di Marco, F., et al. (2017). Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. PULMONARY PHARMACOLOGY & THERAPEUTICS, 45, 148-158 [10.1016/j.pupt.2017.06.002].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_318287";s:6:"handle";s:11:"2108/186997";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:62:"Withdrawal of inhaled corticosteroids in COPD: A meta-analysis";s:9:"metadata6";s:121:"CALZETTA, L; Matera, M; Braido, F; Contoli, M; Corsico, A; Di Marco, F; Santus, P; Scichilone, N; CAZZOLA, M; ROGLIANI, P";s:9:"metadata7";s:26:"10.1016/j.pupt.2017.06.002";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:59;a:14:{s:9:"citazione";s:279:"Calzetta, L., Ora, J., Cavalli, F., Rogliani, P., O'Donnell, D.e., & Cazzola, M. (2017). Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. RESPIRATORY MEDICINE, 129, 189-198 [10.1016/j.rmed.2017.06.020].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_318285";s:6:"handle";s:11:"2108/186995";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:124:"Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis";s:9:"metadata6";s:71:"Calzetta, L; Ora, J; Cavalli, F; Rogliani, P; O'Donnell, De; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.rmed.2017.06.020";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:60;a:14:{s:9:"citazione";s:261:"Calzetta, L., Rogliani, P., Facciolo, F., Rendina, E., Cazzola, M., & Matera, M.g. (2017). Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. EUROPEAN JOURNAL OF PHARMACOLOGY [10.1016/j.ejphar.2017.07.026].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_318295";s:6:"handle";s:11:"2108/187003";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:104:"Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi";s:9:"metadata6";s:73:"Calzetta, L; Rogliani, P; Facciolo, F; Rendina, E; Cazzola, M; Matera, Mg";s:9:"metadata7";s:28:"10.1016/j.ejphar.2017.07.026";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:61;a:14:{s:9:"citazione";s:293:"Calzetta, L., Rogliani, P., Mattei, M., Alfonsi, P., Cito, G., Pistocchini, E., et al. (2017). Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. COPD, 14(5), 526-532 [10.1080/15412555.2017.1344627].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_323770";s:6:"handle";s:11:"2108/191975";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:143:"Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi";s:9:"metadata6";s:96:"Calzetta, L; Rogliani, P; Mattei, M; Alfonsi, P; Cito, G; Pistocchini, E; Cazzola, M; Matera, Mg";s:9:"metadata7";s:29:"10.1080/15412555.2017.1344627";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:62;a:14:{s:9:"citazione";s:237:"Calzetta, L., Rogliani, P., Ora, J., Puxeddu, E., Cazzola, M., & Matera, M.g. (2017). LABA/LAMA combination in copd: A meta-analysis on the duration of treatment. EUROPEAN RESPIRATORY REVIEW, 26(143), 160043 [10.1183/16000617.0043-2016].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_300609";s:6:"handle";s:11:"2108/171459";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:75:"LABA/LAMA combination in copd: A meta-analysis on the duration of treatment";s:9:"metadata6";s:68:"Calzetta, L; Rogliani, P; Ora, J; Puxeddu, E; Cazzola, M; Matera, Mg";s:9:"metadata7";s:26:"10.1183/16000617.0043-2016";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:63;a:14:{s:9:"citazione";s:236:"Cazzola, M., & Rogliani, P. (2017). Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 6(7), 627-636 [10.2217/cer-2017-0037].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_323788";s:6:"handle";s:11:"2108/191993";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:113:"Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease";s:9:"metadata6";s:23:"Cazzola, M; Rogliani, P";s:9:"metadata7";s:21:"10.2217/cer-2017-0037";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:64;a:14:{s:9:"citazione";s:320:"Cazzola, M., & Rogliani, P. (2017). In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids. EVIDENCE-BASED MEDICINE, 22(5), 183-184 [10.1136/ebmed-2017-110726].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_323785";s:6:"handle";s:11:"2108/191989";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:214:"In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids";s:9:"metadata6";s:23:"Cazzola, M; Rogliani, P";s:9:"metadata7";s:25:"10.1136/ebmed-2017-110726";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:65;a:14:{s:9:"citazione";s:247:"Cazzola, M., Calzetta, L., Facciolo, F., Rogliani, P., & Matera, M. (2017). Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. RESPIRATORY RESEARCH, 18(1).";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_300611";s:6:"handle";s:11:"2108/171461";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:141:"Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation";s:9:"metadata6";s:60:"Cazzola, M; Calzetta, L; Facciolo, F; Rogliani, P; Matera, M";s:9:"metadata7";s:25:"10.1186/s12931-016-0500-y";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:66;a:14:{s:9:"citazione";s:235:"Cazzola, M., Calzetta, L., Rinaldi, B., Page, C., Rosano, G., Rogliani, P., et al. (2017). Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. DRUGS, 77(7), 721-732 [10.1007/s40265-017-0731-3].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_309561";s:6:"handle";s:11:"2108/179007";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:92:"Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases";s:9:"metadata6";s:79:"Cazzola, M; Calzetta, L; Rinaldi, B; Page, C; Rosano, G; Rogliani, P; Matera, M";s:9:"metadata7";s:25:"10.1007/s40265-017-0731-3";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:67;a:14:{s:9:"citazione";s:182:"Cazzola, M., Calzetta, L., Rogliani, P., & Matera, M. (2017). The Challenges of Precision Medicine in COPD. MOLECULAR DIAGNOSIS & THERAPY, 21(4), 345-355 [10.1007/s40291-017-0266-z].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_305931";s:6:"handle";s:11:"2108/175605";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:44:"The Challenges of Precision Medicine in COPD";s:9:"metadata6";s:47:"Cazzola, M; Calzetta, L; Rogliani, P; Matera, M";s:9:"metadata7";s:25:"10.1007/s40291-017-0266-z";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:68;a:14:{s:9:"citazione";s:201:"Cazzola, M., Calzetta, L., Rogliani, P., & Matera, M.g. (2017). Tiotropium formulations and safety: a network meta-analysis. THERAPEUTIC ADVANCES IN DRUG SAFETY, 8(1), 17-30 [10.1177/2042098616667304].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_300445";s:6:"handle";s:11:"2108/171318";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:59:"Tiotropium formulations and safety: a network meta-analysis";s:9:"metadata6";s:48:"Cazzola, M; Calzetta, L; Rogliani, P; Matera, Mg";s:9:"metadata7";s:24:"10.1177/2042098616667304";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:69;a:14:{s:9:"citazione";s:195:"Cazzola, M., Ora, J., Rogliani, P., & Matera, M.g. (2017). Role of muscarinic antagonists in asthma therapy. EXPERT REVIEW OF RESPIRATORY MEDICINE, 11(3), 239-253 [10.1080/17476348.2017.1289844].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_305934";s:6:"handle";s:11:"2108/175611";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:48:"Role of muscarinic antagonists in asthma therapy";s:9:"metadata6";s:43:"Cazzola, M; Ora, J; Rogliani, P; Matera, Mg";s:9:"metadata7";s:29:"10.1080/17476348.2017.1289844";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:70;a:14:{s:9:"citazione";s:221:"Cazzola, M., Rogliani, P., Calzetta, L., Hanania, N.a., & Matera, M.g. (2017). Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD, 14(5), 552-563 [10.1080/15412555.2017.1347918].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_323772";s:6:"handle";s:11:"2108/191977";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:87:"Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis";s:9:"metadata6";s:61:"Cazzola, M; Rogliani, P; Calzetta, L; Hanania, Na; Matera, Mg";s:9:"metadata7";s:29:"10.1080/15412555.2017.1347918";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:71;a:14:{s:9:"citazione";s:229:"Cazzola, M., Rogliani, P., Calzetta, L., Lauro, D., Page, C., & Matera, M.g. (2017). Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. TRENDS IN PHARMACOLOGICAL SCIENCES, 38(10), 940-951 [10.1016/j.tips.2017.07.003].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_323776";s:6:"handle";s:11:"2108/191981";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:61:"Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus";s:9:"metadata6";s:67:"Cazzola, M; Rogliani, P; Calzetta, L; Lauro, D; Page, C; Matera, Mg";s:9:"metadata7";s:26:"10.1016/j.tips.2017.07.003";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:72;a:14:{s:9:"citazione";s:272:"Mantero, M., Rogliani, P., Di Pasquale, M., Polverino, E., Crisafulli, E., Guerrero, M., et al. (2017). Acute exacerbations of COPD: Risk factors for failure and relapse. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 12, 2687-2693 [10.2147/COPD.S145253].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_323774";s:6:"handle";s:11:"2108/191979";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:65:"Acute exacerbations of COPD: Risk factors for failure and relapse";s:9:"metadata6";s:116:"Mantero, M; Rogliani, P; Di Pasquale, M; Polverino, E; Crisafulli, E; Guerrero, M; Gramegna, A; Cazzola, M; Blasi, F";s:9:"metadata7";s:20:"10.2147/COPD.S145253";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:73;a:14:{s:9:"citazione";s:171:"Matera, M.g., Rogliani, P., Zanasi, A., & Cazzola, M. (2017). Bronchodilator therapy for chronic cough. PULMONARY PHARMACOLOGY & THERAPEUTICS [10.1016/j.pupt.2017.05.011].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_318292";s:6:"handle";s:11:"2108/187001";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:40:"Bronchodilator therapy for chronic cough";s:9:"metadata6";s:46:"Matera, Mg; Rogliani, P; Zanasi, A; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.pupt.2017.05.011";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:74;a:14:{s:9:"citazione";s:215:"ROGLIANI, P., CALZETTA, L., Coppola, A., Cavalli, F., Ora, J., PUXEDDU, E., et al. (2017). Optimizing drug delivery in COPD: The role of inhaler devices. RESPIRATORY MEDICINE, 124, 6-14 [10.1016/j.rmed.2017.01.006].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_300613";s:6:"handle";s:11:"2108/171463";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:61:"Optimizing drug delivery in COPD: The role of inhaler devices";s:9:"metadata6";s:91:"ROGLIANI, P; CALZETTA, L; Coppola, A; Cavalli, F; Ora, J; PUXEDDU, E; Matera, M; CAZZOLA, M";s:9:"metadata7";s:26:"10.1016/j.rmed.2017.01.006";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:75;a:14:{s:9:"citazione";s:299:"Rogliani, P., Matera, M.g., Ora, J., Cazzola, M., & Calzetta, L. (2017). The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: A quantitative synthesis. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 12, 3469-3485 [10.2147/COPD.S146338].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_323793";s:6:"handle";s:11:"2108/191998";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:123:"The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: A quantitative synthesis";s:9:"metadata6";s:56:"Rogliani, P; Matera, Mg; Ora, J; Cazzola, M; Calzetta, L";s:9:"metadata7";s:20:"10.2147/COPD.S146338";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:76;a:14:{s:9:"citazione";s:183:"Rogliani, P., Ora, J., Puxeddu, E., Matera, M.g., & Cazzola, M. (2017). Adherence to COPD treatment: Myth and reality. RESPIRATORY MEDICINE, 129, 117-123 [10.1016/j.rmed.2017.06.007].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_318283";s:6:"handle";s:11:"2108/186993";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:45:"Adherence to COPD treatment: Myth and reality";s:9:"metadata6";s:55:"Rogliani, P; Ora, J; Puxeddu, E; Matera, Mg; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.rmed.2017.06.007";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:77;a:14:{s:9:"citazione";s:163:"Cazzola, M., Ora, J., & Puxeddu, E. (2016). Dual bronchodilation and exacerbations of COPD. JOURNAL OF THORACIC DISEASE, 8(9), 2383-2386 [10.21037/jtd.2016.08.92].";s:4:"data";s:7:"2016-09";s:2:"id";s:20:"PUBBLICAZIONE_328828";s:6:"handle";s:11:"2108/196146";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:46:"Dual bronchodilation and exacerbations of COPD";s:9:"metadata6";s:30:"Cazzola, M; Ora, J; Puxeddu, E";s:9:"metadata7";s:23:"10.21037/jtd.2016.08.92";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:78;a:14:{s:9:"citazione";s:229:"Calzetta, L., Orlandi, A., Page, C., Rogliani, P., Rinaldi, B., Rosano, G., et al. (2016). Brain natriuretic peptide: Much more than a biomarker. INTERNATIONAL JOURNAL OF CARDIOLOGY, 221, 1031-1038 [10.1016/j.ijcard.2016.07.109].";s:4:"data";s:10:"2016-07-09";s:2:"id";s:20:"PUBBLICAZIONE_287298";s:6:"handle";s:11:"2108/159861";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:52:"Asthma; BNP; COPD; Human airway smooth muscle; NPR-A";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:53:"Brain natriuretic peptide: Much more than a biomarker";s:9:"metadata6";s:92:"Calzetta, L; Orlandi, A; Page, C; Rogliani, P; Rinaldi, B; Rosano, G; Cazzola, M; Matera, Mg";s:9:"metadata7";s:28:"10.1016/j.ijcard.2016.07.109";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:79;a:14:{s:9:"citazione";s:208:"Calzetta, L., Ciaprini, C., Puxeddu, E., & Cazzola, M. (2016). Olodaterol + tiotropium bromide for the treatment of COPD. EXPERT REVIEW OF RESPIRATORY MEDICINE, 10(4), 379-386 [10.1586/17476348.2016.1156538].";s:4:"data";s:7:"2016-04";s:2:"id";s:20:"PUBBLICAZIONE_328818";s:6:"handle";s:11:"2108/196138";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:64:"COPD; fixed-dose combination; olodaterol; phenotypes; tiotropium";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:57:"Olodaterol + tiotropium bromide for the treatment of COPD";s:9:"metadata6";s:48:"Calzetta, L; Ciaprini, C; Puxeddu, E; Cazzola, M";s:9:"metadata7";s:29:"10.1586/17476348.2016.1156538";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:80;a:14:{s:9:"citazione";s:268:"Blasi, F., Page, C., Rossolini, G.m., Pallecchi, L., Matera, M.g., Rogliani, P., et al. (2016). The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. RESPIRATORY MEDICINE, 117, 190-197 [10.1016/j.rmed.2016.06.015].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_294802";s:6:"handle";s:11:"2108/166407";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:90:"Airways infections; Biofilm; Inhaled formulation; N-acetylcysteine; Topical administration";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";s:461:"In airway infections, biofilm formation has been demonstrated to be responsible for both acute and chronic events, and constitutes a genuine challenge in clinical practice. Difficulty in eradicating biofilms with systemic antibiotics has led clinicians to consider the possible role of non-antibiotic therapy. The aim of this review is to examine current evidence for the use of N-acetylcysteine (NAC) in the treatment of biofilm-related respiratory infections.";s:9:"metadata5";s:106:"The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections";s:9:"metadata6";s:83:"Blasi, F; Page, C; Rossolini, Gm; Pallecchi, L; Matera, Mg; Rogliani, P; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.rmed.2016.06.015";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:81;a:14:{s:9:"citazione";s:199:"Calzetta, L., Rogliani, P., Matera, M., & Cazzola, M. (2016). A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. CHEST, 149(5), 1181-1196.";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_291975";s:6:"handle";s:11:"2108/164057";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:110:"A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD";s:9:"metadata6";s:47:"Calzetta, L; Rogliani, P; Matera, M; Cazzola, M";s:9:"metadata7";s:27:"10.1016/j.chest.2016.02.646";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:82;a:14:{s:9:"citazione";s:190:"Cazzola, M., & Rogliani, P. (2016). Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome?. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY [10.1016/j.jaci.2016.04.028].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_291993";s:6:"handle";s:11:"2108/164075";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:134:"Asthma; asthma–chronic obstructive pulmonary disease overlap syndrome; chronic obstructive pulmonary disease; definition; prevalence";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:80:"Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome?";s:9:"metadata6";s:23:"Cazzola, M; Rogliani, P";s:9:"metadata7";s:26:"10.1016/j.jaci.2016.04.028";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:83;a:14:{s:9:"citazione";s:224:"Cazzola, M., & Rogliani, P. (2016). LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients. EVIDENCE-BASED MEDICINE, ebmed-2016-110525 [10.1136/ebmed-2016-110525].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_294815";s:6:"handle";s:11:"2108/166415";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:115:"LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients";s:9:"metadata6";s:23:"Cazzola, M; Rogliani, P";s:9:"metadata7";s:25:"10.1136/ebmed-2016-110525";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:84;a:14:{s:9:"citazione";s:301:"Cazzola, M., Calzetta, L., Puxeddu, E., Ora, J., Facciolo, F., Rogliani, P., et al. (2016). Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. RESPIRATORY RESEARCH, 17(1).";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_291989";s:6:"handle";s:11:"2108/164071";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:179:"Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells";s:9:"metadata6";s:80:"Cazzola, M; Calzetta, L; Puxeddu, E; Ora, J; Facciolo, F; Rogliani, P; Matera, M";s:9:"metadata7";s:25:"10.1186/s12931-016-0386-8";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:85;a:14:{s:9:"citazione";s:234:"Cazzola, M., Calzetta, L., Rogliani, P., & Matera, M.g. (2016). The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON DRUG DISCOVERY, 11(7), 733-744 [10.1080/17460441.2016.1184642].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_291981";s:6:"handle";s:11:"2108/164063";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:87:"The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease";s:9:"metadata6";s:48:"Cazzola, M; Calzetta, L; Rogliani, P; Matera, Mg";s:9:"metadata7";s:29:"10.1080/17460441.2016.1184642";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:86;a:14:{s:9:"citazione";s:246:"Cazzola, M., Calzetta, L., Rogliani, P., Puxeddu, E., Facciolo, F., & Matera, M. (2016). Interaction between corticosteroids and muscarinic antagonists in human airways. PULMONARY PHARMACOLOGY & THERAPEUTICS, 36, 1-9 [10.1016/j.pupt.2015.11.004].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_291969";s:6:"handle";s:11:"2108/164051";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:79:"Interaction between corticosteroids and muscarinic antagonists in human airways";s:9:"metadata6";s:72:"Cazzola, M; Calzetta, L; Rogliani, P; Puxeddu, E; Facciolo, F; Matera, M";s:9:"metadata7";s:26:"10.1016/j.pupt.2015.11.004";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:87;a:14:{s:9:"citazione";s:288:"Cazzola, M., Ora, J., Di Paolo, A., Puxeddu, E., Calzetta, L., & Rogliani, P. (2016). Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 39, 48-53 [10.1016/j.pupt.2016.06.006].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_291991";s:6:"handle";s:11:"2108/164073";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:50:"Budesonide; COPD; Formoterol; Spiromax; Turbuhaler";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:122:"Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD";s:9:"metadata6";s:69:"Cazzola, M; Ora, J; Di Paolo, A; Puxeddu, E; Calzetta, L; Rogliani, P";s:9:"metadata7";s:26:"10.1016/j.pupt.2016.06.006";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:88;a:14:{s:9:"citazione";s:226:"Cazzola, M., Rogliani, P., Ora, J., & Matera, M.g. (2016). Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 17(7), 977-988 [10.1517/14656566.2016.1155555].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_291973";s:6:"handle";s:11:"2108/164055";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:83:"Treatment options for moderate-to-very severe chronic obstructive pulmonary disease";s:9:"metadata6";s:43:"Cazzola, M; Rogliani, P; Ora, J; Matera, Mg";s:9:"metadata7";s:29:"10.1517/14656566.2016.1155555";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:89;a:14:{s:9:"citazione";s:356:"D'Antonio, S., Rogliani, P., Paone, G., Altieri, A., Alma, M.g., Cazzola, M., et al. (2016). An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network. INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 5(2), 244-247 [10.1016/j.ijmyco.2016.04.001].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_291983";s:6:"handle";s:11:"2108/164065";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:173:"An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network";s:9:"metadata6";s:81:"D'Antonio, S; Rogliani, P; Paone, G; Altieri, A; Alma, Mg; Cazzola, M; Puxeddu, E";s:9:"metadata7";s:28:"10.1016/j.ijmyco.2016.04.001";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:90;a:14:{s:9:"citazione";s:317:"Liccardi, G., Salzillo, A., Calzetta, L., Cazzola, M., Matera, M.g., & Rogliani, P. (2016). Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. RESPIRATORY MEDICINE, 117, 150-153 [10.1016/j.rmed.2016.05.026].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_294799";s:6:"handle";s:11:"2108/166401";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:154:"Abdominal pain; Airway hyperreactivity; Anticholinergics; Asthma phenotype; Bronchial asthma; Gastro-esophageal reflux; Increased cholinergic tone; Stress";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:159:"Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics";s:9:"metadata6";s:74:"Liccardi, G; Salzillo, A; Calzetta, L; Cazzola, M; Matera, Mg; Rogliani, P";s:9:"metadata7";s:26:"10.1016/j.rmed.2016.05.026";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:91;a:14:{s:9:"citazione";s:320:"Liccardi, G., Salzillo, A., Calzetta, L., Ora, J., Cazzola, M., Matera, M.g., et al. (2016). Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE, 4(4), 791-793 [10.1016/j.jaip.2016.03.025].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_291995";s:6:"handle";s:11:"2108/164077";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:125:"Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?";s:9:"metadata6";s:82:"Liccardi, G; Salzillo, A; Calzetta, L; Ora, J; Cazzola, M; Matera, Mg; Rogliani, P";s:9:"metadata7";s:26:"10.1016/j.jaip.2016.03.025";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:92;a:14:{s:9:"citazione";s:221:"Matera, M.g., Page, C., Rogliani, P., Calzetta, L., & Cazzola, M. (2016). Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. DRUGS, 76(13), 1257-1270 [10.1007/s40265-016-0625-9].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_294807";s:6:"handle";s:11:"2108/166409";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:92:"Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease";s:9:"metadata6";s:57:"Matera, Mg; Page, C; Rogliani, P; Calzetta, L; Cazzola, M";s:9:"metadata7";s:25:"10.1007/s40265-016-0625-9";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:93;a:14:{s:9:"citazione";s:195:"Matera, M.g., Rogliani, P., Calzetta, L., & Cazzola, M. (2016). Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. DRUG SAFETY, 39(6), 501-508 [10.1007/s40264-016-0402-4].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_291977";s:6:"handle";s:11:"2108/164059";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:73:"Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update";s:9:"metadata6";s:48:"Matera, Mg; Rogliani, P; Calzetta, L; Cazzola, M";s:9:"metadata7";s:25:"10.1007/s40264-016-0402-4";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:94;a:14:{s:9:"citazione";s:290:"ROGLIANI, P., Calzetta, L., Cavalli, F., Matera, M., & CAZZOLA, M. (2016). Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. PULMONARY PHARMACOLOGY & THERAPEUTICS, 40, 95-103 [10.1016/j.pupt.2016.07.009].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_291964";s:6:"handle";s:11:"2108/164047";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:27:"IPF; Meta-analysis; Therapy";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:134:"Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis";s:9:"metadata6";s:59:"ROGLIANI, P; Calzetta, L; Cavalli, F; Matera, M; CAZZOLA, M";s:9:"metadata7";s:26:"10.1016/j.pupt.2016.07.009";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:95;a:14:{s:9:"citazione";s:311:"Rogliani, P., Calzetta, L., Capuani, B., Facciolo, F., Cazzola, M., Lauro, D., et al. (2016). Glucagon-like peptide 1 receptor: A novel pharmacological target for treating human bronchial hyperresponsiveness. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 55(6), 804-814 [10.1165/rcmb.2015-0311OC].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_299405";s:6:"handle";s:11:"2108/170551";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:113:"Glucagon-like peptide 1 receptor: A novel pharmacological target for treating human bronchial hyperresponsiveness";s:9:"metadata6";s:82:"Rogliani, P; Calzetta, L; Capuani, B; Facciolo, F; Cazzola, M; Lauro, D; Matera, M";s:9:"metadata7";s:24:"10.1165/rcmb.2015-0311OC";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:96;a:14:{s:9:"citazione";s:226:"Rogliani, P., Calzetta, L., Cazzola, M., & Matera, M.g. (2016). Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. EXPERT OPINION ON DRUG SAFETY, 15(8), 1133-1146 [10.1080/14740338.2016.1199683].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_291987";s:6:"handle";s:11:"2108/164069";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:80:"Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis";s:9:"metadata6";s:48:"Rogliani, P; Calzetta, L; Cazzola, M; Matera, Mg";s:9:"metadata7";s:29:"10.1080/14740338.2016.1199683";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:97;a:14:{s:9:"citazione";s:211:"Rogliani, P., Ora, J., Puxeddu, E., & Cazzola, M. (2016). Airflow obstruction: Is it asthma or is it COPD?. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 11(1), 3007-3013 [10.2147/COPD.S54927].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_299424";s:6:"handle";s:11:"2108/170567";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:48:"Airflow obstruction: Is it asthma or is it COPD?";s:9:"metadata6";s:43:"Rogliani, P; Ora, J; Puxeddu, E; Cazzola, M";s:9:"metadata7";s:19:"10.2147/COPD.S54927";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:98;a:14:{s:9:"citazione";s:255:"Rogliani, P., Puxeddu, E., Ciaprini, C., Ora, J., Onorato, A., Pezzuto, G., et al. (2016). The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. BIOMED RESEARCH INTERNATIONAL, 2016 [10.1155/2016/4547953].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_299401";s:6:"handle";s:11:"2108/170547";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:103:"The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils";s:9:"metadata6";s:93:"Rogliani, P; Puxeddu, E; Ciaprini, C; Ora, J; Onorato, A; Pezzuto, G; Calzetta, L; Cazzola, M";s:9:"metadata7";s:20:"10.1155/2016/4547953";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:99;a:14:{s:9:"citazione";s:185:"Cazzola, M., Rogliani, P., & Matera, M. (2015). Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. DRUGS, 75(14), 1575-1585 [10.1007/s40265-015-0450-6].";s:4:"data";s:10:"2015-08-28";s:2:"id";s:20:"PUBBLICAZIONE_234211";s:6:"handle";s:11:"2108/115481";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:82:"Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives";s:9:"metadata6";s:34:"Cazzola, M; Rogliani, P; Matera, M";s:9:"metadata7";s:25:"10.1007/s40265-015-0450-6";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:100;a:14:{s:9:"citazione";s:219:"Cazzola, M., Coppola, A., Rogliani, P., & Matera, M. (2015). Novel glucocorticoid receptor agonists in the treatment of asthma. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 24(11), 1473-1482 [10.1517/13543784.2015.1078310].";s:4:"data";s:10:"2015-08-21";s:2:"id";s:20:"PUBBLICAZIONE_234209";s:6:"handle";s:11:"2108/115479";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:102:"AZD5423; GW870086X; SEGRMs; asthma; glucocorticoid receptor agonists; transactivation; transrepression";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";s:1477:"Inhaled corticosteroids are the only drugs that effectively suppress the airway inflammation, but they can induce considerable systemic and adverse effects when they are administered chronically at high doses. Consequently, the pharmaceutical industry is still searching for newer entities with an improved therapeutic index. Areas covered: Herein, the authors review the research in the glucocorticoid field to identify ligands of the glucocorticoid receptor (GR). These ligands preferentially induce transrepression with little or no transactivating activity, in order to have a potent anti-inflammatory action and a low side-effects profile. Expert opinion: Several agents have been synthesized, but few have been tested in experimental models of asthma. Furthermore, only three (BI-54903, GW870086X and AZD5423) have entered clinical development, although the development of at least one of them (BI-54903) was discontinued. The reason for the limited success so far obtained is that the model of transactivation versus transrepression is a too simplistic representation of GR activity. It is difficult to uncouple the therapeutic and harmful effects mediated by GR, but some useful information that might change the current perspective is appearing in the literature. The generation of gene expression 'fingerprints' produced by different GR agonists in target and off-target human tissues could be useful in identifying drug candidates with an improved therapeutic ratio.";s:9:"metadata5";s:65:"Novel glucocorticoid receptor agonists in the treatment of asthma";s:9:"metadata6";s:46:"Cazzola, M; Coppola, A; Rogliani, P; Matera, M";s:9:"metadata7";s:29:"10.1517/13543784.2015.1078310";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:101;a:14:{s:9:"citazione";s:346:"Calzetta, L., Cazzola, M., Page, C.p., Rogliani, P., Facciolo, F., & Matera, M.g. (2015). Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. PULMONARY PHARMACOLOGY & THERAPEUTICS, 32, 15-23 [10.1016/j.pupt.2015.03.007].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_233804";s:6:"handle";s:11:"2108/115097";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:141:"Airway smooth muscle; Asthma; COPD; Glycopyrronium; Human isolated bronchi; RPL554; Relaxant response; Small airways; Synergistic interaction";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";s:418:"The dual PDE3/4 inhibitor RPL 554 causes bronchodilation in patients with asthma or COPD and synergistically interacts with muscarinic receptor antagonists in relaxing human isolated bronchi in acute experimental settings. In the present study we investigated the long-lasting interaction between RPL554 and glycopyrronium by testing these drugs for their ability to relax both medium and small human isolated bronchi.";s:9:"metadata5";s:176:"Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways";s:9:"metadata6";s:71:"Calzetta, L; Cazzola, M; Page, Cp; Rogliani, P; Facciolo, F; Matera, Mg";s:9:"metadata7";s:26:"10.1016/j.pupt.2015.03.007";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:102;a:14:{s:9:"citazione";s:239:"Calzetta, L., Luongo, L., Cazzola, M., Page, C., Rogliani, P., Facciolo, F., et al. (2015). Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. LIFE SCIENCES, 131, 44-50 [10.1016/j.lfs.2015.03.023].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_234188";s:6:"handle";s:11:"2108/115461";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:352:"BHR; Human isolated bronchi; LPS; NK(2) receptor; NKA; Sensory nerves; TRPV1; Anilides; Bronchi; Bronchial Hyperreactivity; Capsaicin; Cinnamates; Electric Stimulation; Female; Humans; Indoles; Lipopolysaccharides; Male; Middle Aged; Muscle Contraction; Neprilysin; Neurokinin A; Piperidines; Sensory Receptor Cells; TRPV Cation Channels; Up-Regulation";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";s:318:"Bacterial lipopolysaccharide (LPS) can induce bronchial hyperresponsiveness (BHR), but the underlying mechanisms remain to be determined. Here, the possible contribution of sensory nerves to LPS-induced BHR was examined in human isolated bronchi to pharmacologically identify the mechanisms underlying this phenomenon.";s:9:"metadata5";s:91:"Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi";s:9:"metadata6";s:116:"Calzetta, L; Luongo, L; Cazzola, M; Page, C; Rogliani, P; Facciolo, F; Maione, S; Capuano, A; Rinaldi, B; Matera, MG";s:9:"metadata7";s:25:"10.1016/j.lfs.2015.03.023";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:103;a:14:{s:9:"citazione";s:329:"Cazzola, M., Calzetta, L., Matera, M.G., Muscoli, S., Rogliani, P., & Romeo, F. (2015). Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. RESPIRATORY MEDICINE, 109(8), 1019-1025 [10.1016/j.rmed.2015.05.021].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_234200";s:6:"handle";s:11:"2108/115473";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:66:"COPD; Comorbidities; Coronary artery disease; Predictive algorithm";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";s:300:"Chronic obstructive pulmonary disease (COPD) is often associated with cardiovascular artery disease (CAD), representing a potential and independent risk factor for cardiovascular morbidity. Therefore, the aim of this study was to identify an algorithm for predicting the risk of CAD in COPD patients.";s:9:"metadata5";s:170:"Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients";s:9:"metadata6";s:70:"Cazzola, M; Calzetta, L; Matera, MG; Muscoli, S; Rogliani, P; Romeo, F";s:9:"metadata7";s:26:"10.1016/j.rmed.2015.05.021";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:104;a:14:{s:9:"citazione";s:259:"Cazzola, M., Calzetta, L., Page, C., Jardim, J., Chuchalin, A., Rogliani, P., et al. (2015). Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. EUROPEAN RESPIRATORY REVIEW, 24(137), 451-461 [10.1183/16000617.00002215].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_234213";s:6:"handle";s:11:"2108/115483";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:90:"Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis";s:9:"metadata6";s:81:"Cazzola, M; Calzetta, L; Page, C; Jardim, J; Chuchalin, A; Rogliani, P; Matera, G";s:9:"metadata7";s:25:"10.1183/16000617.00002215";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:105;a:14:{s:9:"citazione";s:223:"Cazzola, M., Calzetta, L., Segreti, A., Facciolo, F., Rogliani, P., & Matera, M. (2015). Translational study searching for synergy between glycopyrronium and indacaterol. COPD, 12(2), 175-181 [10.3109/15412555.2014.922172].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_208916";s:6:"handle";s:10:"2108/99295";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:80:"Translational study searching for synergy between glycopyrronium and indacaterol";s:9:"metadata6";s:72:"Cazzola, M; Calzetta, L; Segreti, A; Facciolo, F; Rogliani, P; Matera, M";s:9:"metadata7";s:28:"10.3109/15412555.2014.922172";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:106;a:14:{s:9:"citazione";s:173:"Cazzola, M., Rogliani, P., & Matera, M. (2015). Cardiovascular disease in patients with COPD. THE LANCET RESPIRATORY MEDICINE, 3(8), 593-595 [10.1016/S2213-2600(15)00279-9].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_234202";s:6:"handle";s:11:"2108/115475";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:44:"Cardiovascular disease in patients with COPD";s:9:"metadata6";s:34:"Cazzola, M; Rogliani, P; Matera, M";s:9:"metadata7";s:29:"10.1016/S2213-2600(15)00279-9";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:107;a:14:{s:9:"citazione";s:237:"Cazzola, M., Rogliani, P., Ora, J., & Matera, M.g. (2015). Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 8(5), 529-539 [10.1586/17512433.2015.1075389].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_234206";s:6:"handle";s:11:"2108/115616";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:276:"COPD; fixed dose combination; olodaterol; respimat soft mist inhaler; tiotropium bromide; Administration, Inhalation; Animals; Benzoxazines; Bronchodilator Agents; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Tiotropium Bromide";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";s:1030:"A solid scientific rationale and an increasing body of clinical evidence for combining a β2-agonist with an antimuscarinic agent in COPD fully support the opinion that patients not controlled by a single bronchodilator should be given two bronchodilators with different mechanisms of action. Tiotropium is an established choice for the management of patients with stable COPD, and olodaterol is a new effective and safe once-daily long-acting β2-agonist. The parallel bronchodilating modes of action of olodaterol and tiotropium make them an attractive combination in COPD. The large ongoing TOviTO Phase III trial program is documenting the efficacy and safety of olodaterol/tiotropium fixed dose combination delivered via the Respimat Soft Mist Inhaler as maintenance therapy in patients with moderate to very severe COPD. However, we must still know whether this fixed-dose combination will affect exacerbations and hospitalizations, and ultimately death, and also the precise estimates of its relative cardiovascular safety.";s:9:"metadata5";s:90:"Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease";s:9:"metadata6";s:43:"Cazzola, M; Rogliani, P; Ora, J; Matera, Mg";s:9:"metadata7";s:29:"10.1586/17512433.2015.1075389";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:108;a:14:{s:9:"citazione";s:213:"Cazzola, M., Rogliani, P., Sanduzzi, A., & Matera, M.G. (2015). Influence of ethnicity on response to asthma drugs. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 11(7), 1089-1097 [10.1517/17425255.2015.1047341].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_234192";s:6:"handle";s:11:"2108/115465";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:97:"asthma; asthma therapeutics; environmental factors; ethnicity; genetic factors; health care; race";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";s:342:"Understanding variability in the response to asthma medications is essential to ensure appropriate prescribing. Given that there are increased asthma treatment failures observed in ethnic minorities receiving asthma therapeutics, it is fundamental to understand the factors related to ethnicity that can modify the response to asthma therapy.";s:9:"metadata5";s:50:"Influence of ethnicity on response to asthma drugs";s:9:"metadata6";s:48:"Cazzola, M; Rogliani, P; Sanduzzi, A; Matera, MG";s:9:"metadata7";s:29:"10.1517/17425255.2015.1047341";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:109;a:14:{s:9:"citazione";s:201:"Matera, M., Rogliani, P., & Cazzola, M. (2015). Indacaterol for the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 16(1), 107-115 [10.1517/14656566.2015.983076].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_208908";s:6:"handle";s:10:"2108/99289";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:70:"Indacaterol for the treatment of chronic obstructive pulmonary disease";s:9:"metadata6";s:34:"Matera, M; Rogliani, P; Cazzola, M";s:9:"metadata7";s:28:"10.1517/14656566.2015.983076";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:110;a:14:{s:9:"citazione";s:227:"Matera, M.g., Cardaci, V., Cazzola, M., & Rogliani, P. (2015). Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. EXPERT OPINION ON DRUG SAFETY, 14(4), 533-541 [10.1517/14740338.2015.1001363].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_233798";s:6:"handle";s:11:"2108/115091";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:150:"chronic obstructive pulmonary disease; diabetes mellitus; inhaled corticosteroids; local side effects; osteoporosis; pneumonia; systemic side effects.";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";s:362:"The frequent use of inhaled corticosteroids (ICSs), especially at higher doses, has been accompanied by concern about both systemic and local side effects. Patients suffering from chronic obstructive pulmonary disease (COPD) are more at risk from side effects, likely because of the use of higher doses of ICS in COPD to overcome corticosteroid unresponsiveness.";s:9:"metadata5";s:84:"Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease";s:9:"metadata6";s:47:"Matera, Mg; Cardaci, V; Cazzola, M; Rogliani, P";s:9:"metadata7";s:29:"10.1517/14740338.2015.1001363";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:111;a:14:{s:9:"citazione";s:230:"Matera, M.g., Rogliani, P., & Cazzola, M. (2015). QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 16(7), 1079-1090 [10.1517/14656566.2015.1032247].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_233802";s:6:"handle";s:11:"2108/115095";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:85:"QVA149; chronic obstructive pulmonary disease; glycopyrronium; indacaterol; treatment";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";s:602:"The combination of two bronchodilators with different mechanisms of action to treat patients with chronic obstructive pulmonary disease (COPD) is an established medical practice, but the dissimilarities in the onset and duration of action of long-acting β2-agonists (LABA) and long-acting muscarinic agents (LAMA) and differences in the devices used for the delivery of these drugs make free combinations uncomfortable and unpredictable, especially if focused on adherence to prescribed treatment. Therefore, there is the need for fixed-dose combinations (FDCs) of bronchodilators in a single inhaler.";s:9:"metadata5";s:94:"QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease";s:9:"metadata6";s:35:"Matera, Mg; Rogliani, P; Cazzola, M";s:9:"metadata7";s:29:"10.1517/14656566.2015.1032247";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:112;a:14:{s:9:"citazione";s:314:"Rogliani, P., Calzetta, L., Ora, J., Lipsi, R., Segreti, A., Matera, M.g., et al. (2015). Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. EUROPEAN JOURNAL OF PHARMACOLOGY, 761, 383-390 [10.1016/j.ejphar.2015.04.042].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_294844";s:6:"handle";s:11:"2108/166445";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:61:"Aclidinium; COPD; Glycopyrronium; Onset of action; Tiotropium";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";s:1753:"Preclinical studies suggested that aclidinium and glycopyrronium might have a faster onset of action than tiotropium. In this study we assessed the onset of action of aclidinium and glycopyrronium versus tiotropium, all administered at the approved clinical doses, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) and in human isolated bronchi by using different concentrations. Sixteen COPD patients inhaled single doses of aclidinium 400µg, glycopyrronium 50μg and tiotropium 18µg and FEV1 was measured to assess their onset of action. In human isolated bronchi the time to evoke half maximal relaxation of transmural stimulation was tested from 10nM to 1µM for each drug. Nine, eight and twelve patients did not achieve 15% increase of FEV1 after inhalation of aclidinium, glycopyrronium and tiotropium, respectively. Aclidinium (15.6±7.5min) and glycopyrronium (17.9±10.4min) enhanced 15% FEV1 more rapidly than tiotropium (42.5±19.4min), with no significant difference (P>0.05). In isolated airways, glycopyrronium elicited a dose-dependent onset of action (10nM: 8.2±1.3min, 100nM: 7.1±2.1min, 1μM: 3.4±0.4min) that was faster compared to that induced by aclidinium (1μM: 6.4±0.5min) and tiotropium (1μM: 8.4±1.1min) (P<0.05), that halved the contractile tone only at the highest concentration. Bronchodilation induced by aclidinium and glycopyrronium was faster than that induced by tiotropium, but since our analysis was restricted to the acute effect of these LAMAs and the inhaled doses were not isoeffective, the real differences in their impact on the onset of bronchodilation will be definitely determined after a long-term challenge of these treatments at isoeffective doses in COPD patients.";s:9:"metadata5";s:144:"Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi";s:9:"metadata6";s:78:"Rogliani, P; Calzetta, L; Ora, J; Lipsi, R; Segreti, A; Matera, Mg; Cazzola, M";s:9:"metadata7";s:28:"10.1016/j.ejphar.2015.04.042";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:113;a:14:{s:9:"citazione";s:194:"Rogliani, P., Matera, M.g., & Cazzola, M. (2015). Fluticasone furoate/vilanterol combination for the treatment of asthma and COPD. DRUGS OF TODAY, 51(8), 469-478 [10.1358/dot.2015.51.8.2365401].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_294838";s:6:"handle";s:11:"2108/166439";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:79:"Fluticasone furoate/vilanterol combination for the treatment of asthma and COPD";s:9:"metadata6";s:35:"Rogliani, P; Matera, Mg; Cazzola, M";s:9:"metadata7";s:29:"10.1358/dot.2015.51.8.2365401";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:114;a:14:{s:9:"citazione";s:189:"Segreti, A., Calzetta, L., Rogliani, P., & Cazzola, M. (2014). Umeclidinium for the treatment of chronic obstructive pulmonary disease. EXPERT REVIEW OF RESPIRATORY MEDICINE, 8(6), 665-671.";s:4:"data";s:7:"2014-12";s:2:"id";s:20:"PUBBLICAZIONE_208913";s:6:"handle";s:10:"2108/99292";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:71:"Umeclidinium for the treatment of chronic obstructive pulmonary disease";s:9:"metadata6";s:48:"Segreti, A; Calzetta, L; Rogliani, P; Cazzola, M";s:9:"metadata7";s:28:"10.1586/17476348.2014.962519";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:115;a:14:{s:9:"citazione";s:199:"Matera, M., Rogliani, P., Rinaldi, B., & Cazzola, M. (2014). Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 1-7.";s:4:"data";s:10:"2014-11-08";s:2:"id";s:20:"PUBBLICAZIONE_208911";s:6:"handle";s:10:"2108/99290";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:92:"Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease";s:9:"metadata6";s:46:"Matera, M; Rogliani, P; Rinaldi, B; Cazzola, M";s:9:"metadata7";s:28:"10.1586/17512433.2015.977256";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:116;a:14:{s:9:"citazione";s:272:"Cazzola, M., Calzetta, L., Page, C., Rogliani, P., Facciolo, F., Gavaldà, A., et al. (2014). Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. EUROPEAN JOURNAL OF PHARMACOLOGY, 745C, 135-143.";s:4:"data";s:10:"2014-10-22";s:2:"id";s:20:"PUBBLICAZIONE_210954";s:6:"handle";s:11:"2108/100089";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:128:"Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi";s:9:"metadata6";s:82:"Cazzola, M; Calzetta, L; Page, C; Rogliani, P; Facciolo, F; Gavaldà, A; Matera, M";s:9:"metadata7";s:28:"10.1016/j.ejphar.2014.10.025";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:117;a:14:{s:9:"citazione";s:284:"Novelli, F., Latorre, M., Vergura, L., Caiaffa, M., Camiciottoli, G., Guarnieri, G., et al. (2014). Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy. PULMONARY PHARMACOLOGY & THERAPEUTICS [10.1016/j.pupt.2014.09.007].";s:4:"data";s:10:"2014-09-30";s:2:"id";s:20:"PUBBLICAZIONE_208915";s:6:"handle";s:10:"2108/99294";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:115:"Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy";s:9:"metadata6";s:162:"Novelli, F; Latorre, M; Vergura, L; Caiaffa, M; Camiciottoli, G; Guarnieri, G; Matucci, A; Macchia, L; Vianello, A; Vultaggio, A; Celi, A; Cazzola, M; Paggiaro, P";s:9:"metadata7";s:26:"10.1016/j.pupt.2014.09.007";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:118;a:14:{s:9:"citazione";s:181:"Matera, M., Page, C., & Cazzola, M. (2014). PDE inhibitors currently in early clinical trials for the treatment of asthma. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 23(9), 1267-1275.";s:4:"data";s:7:"2014-09";s:2:"id";s:20:"PUBBLICAZIONE_188668";s:6:"handle";s:10:"2108/90075";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:77:"PDE inhibitors currently in early clinical trials for the treatment of asthma";s:9:"metadata6";s:30:"Matera, M; Page, C; Cazzola, M";s:9:"metadata7";s:28:"10.1517/13543784.2014.921157";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:119;a:14:{s:9:"citazione";s:194:"Bousquet, J., Addis, A., Adcock, I., Agache, I., Agusti, A., Alonso, A., et al. (2014). Integrated care pathways for airway diseases (AIRWAYS-ICPs). EUROPEAN RESPIRATORY JOURNAL, 44(2), 304-323.";s:4:"data";s:7:"2014-08";s:2:"id";s:20:"PUBBLICAZIONE_188667";s:6:"handle";s:10:"2108/90076";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:59:"Integrated care pathways for airway diseases (AIRWAYS-ICPs)";s:9:"metadata6";s:2666:"Bousquet, J; Addis, A; Adcock, I; Agache, I; Agusti, A; Alonso, A; Annesi-Maesano, I; Anto, J; Bachert, C; Baena-Cagnani, C; Bai, C; Baigenzhin, A; Barbara, C; Barnes, P; Bateman, E; Beck, L; Bedbrook, A; Bel, E; Benezet, O; Bennoor, K; Benson, M; Bernabeu-Wittel, M; Bewick, M; Bindslev-Jensen, C; Blain, H; Blasi, F; Bonini, M; Bonini, S; Boulet, L; Bourdin, A; Bourret, R; Bousquet, P; Brightling, C; Briggs, A; Brozek, J; Buhl, R; Bush, A; Caimmi, D; Calderon, M; Calverley, P; Camargos, P; Camuzat, T; Canonica, G; Carlsen, K; Casale, T; Cazzola, M; Cepeda Sarabia, A; Cesario, A; Chen, Y; Chkhartishvili, E; Chavannes, N; Chiron, R; Chuchalin, A; Chung, K; Cox, L; Crooks, G; Crooks, M; Cruz, A; Custovic, A; Dahl, R; Dahlen, S; De Blay, F; Dedeu, T; Deleanu, D; Demoly, P; Devillier, P; Didier, A; Dinh-Xuan, A; Djukanovic, R; Dokic, D; Douagui, H; Dubakiene, R; Eglin, S; Elliot, F; Emuzyte, R; Fabbri, L; Fink Wagner, A; Fletcher, M; Fokkens, W; Fonseca, J; Franco, A; Frith, P; Furber, A; Gaga, M; Garcés, J; Garcia-Aymerich, J; Gamkrelidze, A; Gonzales-Diaz, S; Gouzi, F; Guzmán, M; Haahtela, T; Harrison, D; Hayot, M; Heaney, L; Heinrich, J; Hellings, P; Hooper, J; Humbert, M; Hyland, M; Iaccarino, G; Jakovenko, D; Jardim, J; Jeandel, C; Jenkins, C; Johnston, S; Jonquet, O; Joos, G; Jung, K; Kalayci, O; Karunanithi, S; Keil, T; Khaltaev, N; Kolek, V; Kowalski, M; Kull, I; Kuna, P; Kvedariene, V; Le, L; Lodrup Carlsen, K; Louis, R; MacNee, W; Mair, A; Majer, I; Manning, P; de Manuel Keenoy, E; Masjedi, M; Melen, E; Melo-Gomes, E; Menzies-Gow, A; Mercier, G; Mercier, J; Michel, J; Miculinic, N; Mihaltan, F; Milenkovic, B; Molimard, M; Momas, I; Montilla-Santana, A; Morais-Almeida, M; Morgan, M; N'Diaye, M; Nafti, S; Nekam, K; Neou, A; Nicod, L; O'Hehir, R; Ohta, K; Paggiaro, P; Palkonen, S; Palmer, S; Papadopoulos, N; Papi, A; Passalacqua, G; Pavord, I; Pigearias, B; Plavec, D; Postma, D; Price, D; Rabe, K; Radier Pontal, F; Redon, J; Rennard, S; Roberts, J; Robine, J; Roca, J; Roche, N; Rodenas, F; Roggeri, A; Rolland, C; Rosado-Pinto, J; Ryan, D; Samolinski, B; Sanchez-Borges, M; Schünemann, H; Sheikh, A; Shields, M; Siafakas, N; Sibille, Y; Similowski, T; Small, I; Sola-Morales, O; Sooronbaev, T; Stelmach, R; Sterk, P; Stiris, T; Sud, P; Tellier, V; To, T; Todo-Bom, A; Triggiani, M; Valenta, R; Valero, A; Valiulis, A; Valovirta, E; Van Ganse, E; Vandenplas, O; Vasankari, T; Vestbo, J; Vezzani, G; Viegi, G; Visier, L; Vogelmeier, C; Vontetsianos, T; Wagstaff, R; Wahn, U; Wallaert, B; Whalley, B; Wickman, M; Williams, D; Wilson, N; Yawn, B; Yiallouros, P; Yorgancioglu, A; Yusuf, O; Zar, H; Zhong, N; Zidarn, M; Zuberbier, T";s:9:"metadata7";s:25:"10.1183/09031936.00014614";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:120;a:14:{s:9:"citazione";s:167:"Page, C., & Cazzola, M. (2014). Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. EUROPEAN RESPIRATORY JOURNAL, 44(2), 475-482.";s:4:"data";s:7:"2014-08";s:2:"id";s:20:"PUBBLICAZIONE_188669";s:6:"handle";s:10:"2108/90087";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:88:"Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease";s:9:"metadata6";s:19:"Page, C; Cazzola, M";s:9:"metadata7";s:25:"10.1183/09031936.00003814";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:121;a:14:{s:9:"citazione";s:222:"Papi, A., Blasi, F., Canonica, G., Cazzola, M., Centanni, S., Foschino Barbaro, M., et al. (2014). Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage. EUROPEAN JOURNAL OF INTERNAL MEDICINE.";s:4:"data";s:10:"2014-07-19";s:2:"id";s:20:"PUBBLICAZIONE_188665";s:6:"handle";s:10:"2108/90077";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:83:"Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage";s:9:"metadata6";s:141:"Papi, A; Blasi, F; Canonica, G; Cazzola, M; Centanni, S; Foschino Barbaro, M; Melani, A; Paggiaro, P; Ricciardolo, F; Rossi, A; Scichilone, N";s:9:"metadata7";s:26:"10.1016/j.ejim.2014.06.022";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:122;a:14:{s:9:"citazione";s:151:"Cazzola, M., & Segreti, A. (2014). Omalizumab: stepping outside our comfort zone to broaden the number of those who can benefit. DRUGS, 74(5), 535-537.";s:4:"data";s:7:"2014-04";s:2:"id";s:20:"PUBBLICAZIONE_188682";s:6:"handle";s:10:"2108/90078";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:92:"Omalizumab: stepping outside our comfort zone to broaden the number of those who can benefit";s:9:"metadata6";s:22:"Cazzola, M; Segreti, A";s:9:"metadata7";s:25:"10.1007/s40265-014-0205-9";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:123;a:14:{s:9:"citazione";s:145:"Matera, M., Calzetta, L., Rogliani, P., Cesario, A., & Cazzola, M. (2014). New Treatments for COPD in the Elderly. CURRENT PHARMACEUTICAL DESIGN.";s:4:"data";s:10:"2014-03-14";s:2:"id";s:20:"PUBBLICAZIONE_188486";s:6:"handle";s:10:"2108/89637";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:38:"New Treatments for COPD in the Elderly";s:9:"metadata6";s:59:"Matera, M; Calzetta, L; Rogliani, P; Cesario, A; Cazzola, M";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:124;a:14:{s:9:"citazione";s:341:"Calzetta, L., Passeri, D., Kanabar, V., Rogliani, P., Page, C., Cazzola, M., et al. (2014). Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 50(3), 493-501 [10.1165/rcmb.2013-0119OC].";s:4:"data";s:7:"2014-03";s:2:"id";s:20:"PUBBLICAZIONE_183569";s:6:"handle";s:10:"2108/88501";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:145:"Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism";s:9:"metadata6";s:92:"Calzetta, L; Passeri, D; Kanabar, V; Rogliani, P; Page, C; Cazzola, M; Matera, M; Orlandi, A";s:9:"metadata7";s:24:"10.1165/rcmb.2013-0119OC";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:125;a:14:{s:9:"citazione";s:113:"Cazzola, M., & Matera, M. (2014). Bronchodilators: current and future. CLINICS IN CHEST MEDICINE, 35(1), 191-201.";s:4:"data";s:7:"2014-03";s:2:"id";s:20:"PUBBLICAZIONE_188704";s:6:"handle";s:10:"2108/90086";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:35:"Bronchodilators: current and future";s:9:"metadata6";s:21:"Cazzola, M; Matera, M";s:9:"metadata7";s:25:"10.1016/j.ccm.2013.10.005";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:126;a:14:{s:9:"citazione";s:140:"Cazzola, M., & Matera, M. (2014). N-acetylcysteine in COPD may be beneficial, but for whom?. THE LANCET RESPIRATORY MEDICINE, 2(3), 166-167.";s:4:"data";s:7:"2014-03";s:2:"id";s:20:"PUBBLICAZIONE_188702";s:6:"handle";s:10:"2108/90088";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:57:"N-acetylcysteine in COPD may be beneficial, but for whom?";s:9:"metadata6";s:21:"Cazzola, M; Matera, M";s:9:"metadata7";s:29:"10.1016/S2213-2600(13)70294-7";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:127;a:14:{s:9:"citazione";s:197:"Cazzola, M., Calzetta, L., Page, C., & Matera, M. (2014). Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 10(1), 129-137.";s:4:"data";s:7:"2014-01";s:2:"id";s:20:"PUBBLICAZIONE_188707";s:6:"handle";s:10:"2108/90084";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:74:"Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation";s:9:"metadata6";s:43:"Cazzola, M; Calzetta, L; Page, C; Matera, M";s:9:"metadata7";s:28:"10.1517/17425255.2014.865723";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:128;a:14:{s:9:"citazione";s:236:"Calzetta, L., Rogliani, P., Cazzola, M., & Matera, M. (2014). Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond. EXPERT OPINION ON DRUG DISCOVERY, 9(6), 595-607 [10.1517/17460441.2014.909403].";s:4:"data";s:4:"2014";s:2:"id";s:20:"PUBBLICAZIONE_188484";s:6:"handle";s:10:"2108/89651";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:93:"Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond";s:9:"metadata6";s:47:"Calzetta, L; Rogliani, P; Cazzola, M; Matera, M";s:9:"metadata7";s:28:"10.1517/17460441.2014.909403";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:129;a:14:{s:9:"citazione";s:179:"Cazzola, M., & Matera, M. (2014). Triple combinations in chronic obstructive pulmonary disease – is three better than two?. EXPERT OPINION ON PHARMACOTHERAPY, 15(17), 2475-2478.";s:4:"data";s:4:"2014";s:2:"id";s:20:"PUBBLICAZIONE_208912";s:6:"handle";s:10:"2108/99291";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:90:"Triple combinations in chronic obstructive pulmonary disease – is three better than two?";s:9:"metadata6";s:21:"Cazzola, M; Matera, M";s:9:"metadata7";s:28:"10.1517/14656566.2014.972367";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:130;a:14:{s:9:"citazione";s:238:"Cesario, A., Auffray, C., Agusti, A., Apolone, G., Balling, R., Barbanti, P., et al. (2014). A systems medicine clinical platform for understanding and managing non- communicable diseases. CURRENT PHARMACEUTICAL DESIGN, 20(38), 5945-5956.";s:4:"data";s:4:"2014";s:2:"id";s:20:"PUBBLICAZIONE_220070";s:6:"handle";s:11:"2108/105702";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:31:"Settore MED/13 - Endocrinologia";s:9:"metadata4";N;s:9:"metadata5";s:94:"A systems medicine clinical platform for understanding and managing non- communicable diseases";s:9:"metadata6";s:560:"Cesario, A; Auffray, C; Agusti, A; Apolone, G; Balling, R; Barbanti, P; Bellia, A; Boccia, S; Bousquet, J; Cardaci, V; Cazzola, M; Dall'Armi, V; Daraselia, N; Ros, L; Bufalo, A; Ducci, G; Ferri, L; Fini, M; Fossati, C; Gensini, G; Granone, P; Kinross, J; Lauro, D; Cascio, G; Lococo, F; Lococo, A; Maier, D; Marcus, F; Margaritora, S; Marra, C; Minati, G; Neri, M; Pasqua, F; Pison, C; Pristipino, C; Roca, J; Rosano, G; Rossini, P; Russo, P; Salinaro, G; Shenhar, S; Soreq, H; Sterk, P; Stocchi, F; Torti, M; Volterrani, M; Wouters, E; Frustaci, A; Bonassi, S";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:131;a:14:{s:9:"citazione";s:223:"Lipsi, R., Rogliani, P., Calzetta, L., Segreti, A., & Cazzola, M. (2014). The clinical use of regenerative therapy in COPD. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 9, 1389-1396 [10.2147/COPD.S49519].";s:4:"data";s:4:"2014";s:2:"id";s:20:"PUBBLICAZIONE_233796";s:6:"handle";s:11:"2108/115089";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:311:"all-trans retinoic acid; chronic obstructive pulmonary disease; photobiostimulation; regenerative therapy; stem cells; Animals; Humans; Laser Therapy, Low-Level; Lung; Pulmonary Disease, Chronic Obstructive; Recovery of Function; Regenerative Medicine; Treatment Outcome; Regeneration; Stem Cell Transplantation";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";s:1064:"Regenerative or stem cell therapy is an emerging field of treatment based on stimulation of endogenous resident stem cells or administration of exogenous stem cells to treat diseases or injury and to replace malfunctioning or damaged tissues. Current evidence suggests that in the lung, these cells may participate in tissue homeostasis and regeneration after injury. Animal and human studies have demonstrated that tissue-specific stem cells and bone marrow-derived cells contribute to lung tissue regeneration and protection, and thus administration of exogenous stem/progenitor cells or humoral factors responsible for the activation of endogenous stem/progenitor cells may be a potent next-generation therapy for chronic obstructive pulmonary disease. The use of bone marrow-derived stem cells could allow repairing and regenerate the damaged tissue present in chronic obstructive pulmonary disease by means of their engraftment into the lung. Another approach could be the stimulation of resident stem cells by means of humoral factors or photobiostimulation.";s:9:"metadata5";s:48:"The clinical use of regenerative therapy in COPD";s:9:"metadata6";s:58:"Lipsi, R; Rogliani, P; Calzetta, L; Segreti, A; Cazzola, M";s:9:"metadata7";s:19:"10.2147/COPD.S49519";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:132;a:14:{s:9:"citazione";s:221:"Matera, M., Rogliani, P., & Cazzola, M. (2014). Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 15(7), 961-977 [10.1517/14656566.2014.899581].";s:4:"data";s:4:"2014";s:2:"id";s:20:"PUBBLICAZIONE_188485";s:6:"handle";s:10:"2108/89640";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:90:"Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease";s:9:"metadata6";s:34:"Matera, M; Rogliani, P; Cazzola, M";s:9:"metadata7";s:28:"10.1517/14656566.2014.899581";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:133;a:14:{s:9:"citazione";s:215:"Matera, M., Rogliani, P., Calzetta, L., & Cazzola, M. (2014). Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?. DRUGS, 74(17), 1983-1992 [10.1007/s40265-014-0303-8].";s:4:"data";s:4:"2014";s:2:"id";s:20:"PUBBLICAZIONE_208914";s:6:"handle";s:10:"2108/99293";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:76:"Humans; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive";s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";s:1770:"Phosphodiesterase-4 (PDE4) inhibitors have broad anti-inflammatory activity, inhibiting the airway inflammation associated with chronic obstructive pulmonary disease (COPD), especially by reducing airway neutrophils that are key cells in COPD. A careful evaluation of the results of several meta-analyses allows us to consider the use of PDE4 inhibitors as very important in those patients with COPD who are particularly susceptible to exacerbations, the so-called 'frequent exacerbators'. Consequently, PDE4 inhibitors should be used earlier and more frequently than is the case today, but they are prescribed sporadically because of side effects. Several strategies are conceivable to avoid side effects, but, unfortunately, many of these approaches are yet to be successfully translated into clinical effectiveness after several decades of research. A novel alternative approach is to administer multiple drugs simultaneously or drugs capable of two distinct primary pharmacological actions based on distinct pharmacophores (bifunctional drugs) in order to produce additive or synergistic effects and, consequently, to dispense these drugs at lower doses, inducing fewer side effects. The fact that we have realized that there is a need to target simultaneously more PDEs unquestionably represents an advance in the possible use of PDE inhibitors. Actually, the possibility that multivalent (multifunctional) ligands, which feature two or more pharmacophores, may deliver superior efficacy is an approach that is being explored. Recognizing the role of specific targeted therapy aimed at subcellular domains has changed our understanding of the use of PDE inhibitors, and offers an opportunity to improve both the therapeutic tolerability and efficacy of these drugs.";s:9:"metadata5";s:98:"Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?";s:9:"metadata6";s:47:"Matera, M; Rogliani, P; Calzetta, L; Cazzola, M";s:9:"metadata7";s:25:"10.1007/s40265-014-0303-8";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:134;a:14:{s:9:"citazione";s:174:"Rogliani, P., Calzetta, L., Segreti, A., Barrile, A., & Cazzola, M. (2014). Diabetes mellitus among outpatients with COPD attending a university hospital. ACTA DIABETOLOGICA.";s:4:"data";s:4:"2014";s:2:"id";s:20:"PUBBLICAZIONE_175940";s:6:"handle";s:10:"2108/89668";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:78:"Diabetes mellitus among outpatients with COPD attending a university hospital.";s:9:"metadata6";s:60:"Rogliani, P; Calzetta, L; Segreti, A; Barrile, A; Cazzola, M";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:135;a:14:{s:9:"citazione";s:250:"Rogliani, P., Ora, J., Ciaprini, C., Senis, L., Stirpe, E., & Cazzola, M. (2014). Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. RESPIRATORY MEDICINE, 108(2), 307-313 [10.1016/j.rmed.2013.10.022].";s:4:"data";s:4:"2014";s:2:"id";s:20:"PUBBLICAZIONE_188487";s:6:"handle";s:10:"2108/89632";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:99:"Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD";s:9:"metadata6";s:65:"Rogliani, P; Ora, J; Ciaprini, C; Senis, L; Stirpe, E; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.rmed.2013.10.022";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:136;a:14:{s:9:"citazione";s:199:"Segreti, A., Stirpe, E., Rogliani, P., & Cazzola, M. (2014). Defining Phenotypes in COPD: An Aid to Personalized Healthcare. MOLECULAR DIAGNOSIS & THERAPY, 18(4), 381-388 [10.1007/s40291-014-0100-9].";s:4:"data";s:4:"2014";s:2:"id";s:20:"PUBBLICAZIONE_188483";s:6:"handle";s:10:"2108/89643";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:62:"Defining Phenotypes in COPD: An Aid to Personalized Healthcare";s:9:"metadata6";s:46:"Segreti, A; Stirpe, E; Rogliani, P; Cazzola, M";s:9:"metadata7";s:25:"10.1007/s40291-014-0100-9";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:137;a:14:{s:9:"citazione";s:333:"Franciosi, L., Diamant, Z., Banner, K., Zuiker, R., Morelli, N., Kamerling, I., et al. (2013). Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. THE LANCET RESPIRATORY MEDICINE, 1(9), 714-727.";s:4:"data";s:7:"2013-11";s:2:"id";s:20:"PUBBLICAZIONE_188705";s:6:"handle";s:10:"2108/90085";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:189:"Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials";s:9:"metadata6";s:172:"Franciosi, L; Diamant, Z; Banner, K; Zuiker, R; Morelli, N; Kamerling, I; de Kam, M; Burggraaf, J; Cohen, A; Cazzola, M; Calzetta, L; Singh, D; Spina, D; Walker, M; Page, C";s:9:"metadata7";s:29:"10.1016/S2213-2600(13)70187-5";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:138;a:14:{s:9:"citazione";s:221:"Braido, F., Baiardini, I., Cazzola, M., Brusselle, G., Marugo, F., & Canonica, G. (2013). Long-acting bronchodilators improve health related quality of life in patients with COPD. RESPIRATORY MEDICINE, 107(10), 1465-1480.";s:4:"data";s:7:"2013-10";s:2:"id";s:20:"PUBBLICAZIONE_188715";s:6:"handle";s:10:"2108/90079";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:88:"Long-acting bronchodilators improve health related quality of life in patients with COPD";s:9:"metadata6";s:73:"Braido, F; Baiardini, I; Cazzola, M; Brusselle, G; Marugo, F; Canonica, G";s:9:"metadata7";s:26:"10.1016/j.rmed.2013.08.007";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:139;a:14:{s:9:"citazione";s:171:"Cazzola, M., Lopez-Campos, J., & Puente-Maestu, L. (2013). The MABA approach: a new option to improve bronchodilator therapy. EUROPEAN RESPIRATORY JOURNAL, 42(4), 885-887.";s:4:"data";s:7:"2013-10";s:2:"id";s:20:"PUBBLICAZIONE_188714";s:6:"handle";s:10:"2108/90080";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:65:"The MABA approach: a new option to improve bronchodilator therapy";s:9:"metadata6";s:45:"Cazzola, M; Lopez-Campos, J; Puente-Maestu, L";s:9:"metadata7";s:25:"10.1183/09031936.00067013";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:140;a:14:{s:9:"citazione";s:175:"Matera, M., Calzetta, L., & Cazzola, M. (2013). β-Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives. DRUGS, 73(15), 1653-1663.";s:4:"data";s:7:"2013-10";s:2:"id";s:20:"PUBBLICAZIONE_188713";s:6:"handle";s:10:"2108/90082";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:100:"β-Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives";s:9:"metadata6";s:34:"Matera, M; Calzetta, L; Cazzola, M";s:9:"metadata7";s:25:"10.1007/s40265-013-0120-5";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:141;a:14:{s:9:"citazione";s:164:"Cazzola, M., Bardaro, F., & Stirpe, E. (2013). The role of indacaterol for chronic obstructive pulmonary disease (COPD). JOURNAL OF THORACIC DISEASE, 5(4), 559-566.";s:4:"data";s:7:"2013-08";s:2:"id";s:20:"PUBBLICAZIONE_188716";s:6:"handle";s:10:"2108/90081";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:72:"The role of indacaterol for chronic obstructive pulmonary disease (COPD)";s:9:"metadata6";s:33:"Cazzola, M; Bardaro, F; Stirpe, E";s:9:"metadata7";s:35:"10.3978/j.issn.2072-1439.2013.07.35";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:142;a:14:{s:9:"citazione";s:285:"Alessandrino, E.P., Porta, M., Malcovati, L., Jackson, C.H., Pascutto, C., Bacigalupo, A., et al. (2013). Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. AMERICAN JOURNAL OF HEMATOLOGY, 88(7), 581-588 [10.1002/ajh.23458].";s:4:"data";s:7:"2013-07";s:2:"id";s:20:"PUBBLICAZIONE_254642";s:6:"handle";s:11:"2108/248346";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/15";s:9:"metadata4";N;s:9:"metadata5";s:110:"Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome";s:9:"metadata6";s:267:"Alessandrino, EP; Porta, MGD; Malcovati, L; Jackson, CH; Pascutto, C; Bacigalupo, A; Teresa van Lint, M; Falda, M; Bernardi, M; Onida, F; Guidi, S; Iori, AP; Cerretti, R; Marenco, P; Pioltelli, P; Angelucci, E; Oneto, R; Ripamonti, F; Rambaldi, A; Bosi, A; Cazzola, M";s:9:"metadata7";s:17:"10.1002/ajh.23458";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:143;a:14:{s:9:"citazione";s:197:"Cazzola, M., Page, C., & Matera, M. (2013). Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. PULMONARY PHARMACOLOGY & THERAPEUTICS [10.1016/j.pupt.2012.12.006].";s:4:"data";s:7:"2013-06";s:2:"id";s:20:"PUBBLICAZIONE_162527";s:6:"handle";s:10:"2108/78157";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:85:"Long-acting muscarinic receptor antagonists for the treatment of respiratory disease.";s:9:"metadata6";s:32:"Cazzola, M; Page, C; Matera, MG.";s:9:"metadata7";s:26:"10.1016/j.pupt.2012.12.006";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:144;a:14:{s:9:"citazione";s:190:"Cazzola, M., Page, C.P., & Matera, M. (2013). Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY [10.1517/14656566.2013.789021].";s:4:"data";s:7:"2013-06";s:2:"id";s:20:"PUBBLICAZIONE_162543";s:6:"handle";s:10:"2108/78160";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:77:"Aclidinium bromide for the treatment of chronic obstructive pulmonary disease";s:9:"metadata6";s:33:"Cazzola, M; Page, CP; Matera, MG.";s:9:"metadata7";s:28:"10.1517/14656566.2013.789021";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:145;a:14:{s:9:"citazione";s:340:"Cazzola, M., Brusasco, V., Centanni, S., Cerveri, I., De Michele, F., Di Maria, G., et al. (2013). Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists. PULMONARY PHARMACOLOGY & THERAPEUTICS, 26(2), 218-228.";s:4:"data";s:7:"2013-04";s:2:"id";s:20:"PUBBLICAZIONE_188746";s:6:"handle";s:10:"2108/90268";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:185:"Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists";s:9:"metadata6";s:136:"Cazzola, M; Brusasco, V; Centanni, S; Cerveri, I; De Michele, F; Di Maria, G; Palange, P; Pellegrino, R; Polverino, M; Rossi, A; Papi, A";s:9:"metadata7";s:26:"10.1016/j.pupt.2012.10.010";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:146;a:14:{s:9:"citazione";s:251:"Cazzola, M., Rogliani, P., & Matera, M. (2013). Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 14(6), 775-781 [10.1517/14656566.2013.776539].";s:4:"data";s:7:"2013-04";s:2:"id";s:20:"PUBBLICAZIONE_188742";s:6:"handle";s:10:"2108/90287";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:120:"Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease";s:9:"metadata6";s:34:"Cazzola, M; Rogliani, P; Matera, M";s:9:"metadata7";s:28:"10.1517/14656566.2013.776539";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:147;a:14:{s:9:"citazione";s:259:"Cazzola, M., Segreti, A., Stirpe, E., Puxeddu, E., Ora, J., Rogliani, P., et al. (2013). Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. RESPIRATORY MEDICINE, 107(1), 107-111 [10.1016/j.rmed.2012.09.022].";s:4:"data";s:7:"2013-01";s:2:"id";s:20:"PUBBLICAZIONE_162014";s:6:"handle";s:10:"2108/79148";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:102:"Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.";s:9:"metadata6";s:79:"Cazzola, M; Segreti, A; Stirpe, E; Puxeddu, E; Ora, J; Rogliani, P; Matera, MG.";s:9:"metadata7";s:26:"10.1016/j.rmed.2012.09.022";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:148;a:14:{s:9:"citazione";s:295:"Calzetta, L., Page, C., Spina, D., Cazzola, M., Rogliani, P., Facciolo, F., et al. (2013). Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 346(3), 414-423 [10.1124/jpet.113.204644].";s:4:"data";s:4:"2013";s:2:"id";s:20:"PUBBLICAZIONE_205007";s:6:"handle";s:10:"2108/97429";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:105:"Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone";s:9:"metadata6";s:79:"Calzetta, L; Page, C; Spina, D; Cazzola, M; Rogliani, P; Facciolo, F; Matera, M";s:9:"metadata7";s:23:"10.1124/jpet.113.204644";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:149;a:14:{s:9:"citazione";s:260:"Cazzola, M., Calzetta, L., Lauro, D., Bettoncelli, G., Cricelli, C., DI DANIELE, N., et al. (2013). Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit. RESPIRATORY MEDICINE, 107(9), 1417-1422 [10.1016/j.rmed.2013.04.021].";s:4:"data";s:4:"2013";s:2:"id";s:20:"PUBBLICAZIONE_205008";s:6:"handle";s:10:"2108/97437";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:89:"Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit";s:9:"metadata6";s:90:"Cazzola, M; Calzetta, L; Lauro, D; Bettoncelli, G; Cricelli, C; DI DANIELE, N; Rogliani, P";s:9:"metadata7";s:26:"10.1016/j.rmed.2013.04.021";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:150;a:14:{s:9:"citazione";s:200:"Cazzola, M., Page, C., Rogliani, P., & Matera, M. (2013). β2-Agonist Therapy in Lung Disease. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 187(7), 690-696 [10.1164/rccm.201209-1739PP].";s:4:"data";s:4:"2013";s:2:"id";s:20:"PUBBLICAZIONE_188490";s:6:"handle";s:10:"2108/89635";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:35:"β2-Agonist Therapy in Lung Disease";s:9:"metadata6";s:43:"Cazzola, M; Page, C; Rogliani, P; Matera, M";s:9:"metadata7";s:26:"10.1164/rccm.201209-1739PP";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:151;a:14:{s:9:"citazione";s:212:"Cazzola, M., Rogliani, P., Novelli, L., & Matera, M. (2013). Inhaled corticosteroids for chronic obstructive pulmonary disease. EXPERT OPINION ON PHARMACOTHERAPY, 14(18), 2489-2499 [10.1517/14656566.2013.848856].";s:4:"data";s:4:"2013";s:2:"id";s:20:"PUBBLICAZIONE_188488";s:6:"handle";s:10:"2108/89634";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:65:"Inhaled corticosteroids for chronic obstructive pulmonary disease";s:9:"metadata6";s:46:"Cazzola, M; Rogliani, P; Novelli, L; Matera, M";s:9:"metadata7";s:28:"10.1517/14656566.2013.848856";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:152;a:14:{s:9:"citazione";s:248:"Cazzola, M., Rogliani, P., Ruggeri, P., Segreti, A., Proietto, A., Picciolo, S., et al. (2013). Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. RESPIRATORY MEDICINE, 107(6), 848-853 [10.1016/j.rmed.2013.02.008].";s:4:"data";s:4:"2013";s:2:"id";s:20:"PUBBLICAZIONE_205013";s:6:"handle";s:10:"2108/97444";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:83:"Chronic treatment with indacaterol and airway response to salbutamol in stable COPD";s:9:"metadata6";s:84:"Cazzola, M; Rogliani, P; Ruggeri, P; Segreti, A; Proietto, A; Picciolo, S; Matera, M";s:9:"metadata7";s:26:"10.1016/j.rmed.2013.02.008";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:153;a:14:{s:9:"citazione";s:187:"Cazzola, M., Segreti, A., & Matera, M. (2013). New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. DRUG DESIGN, DEVELOPMENT AND THERAPY, 7, 1201-1208.";s:4:"data";s:4:"2013";s:2:"id";s:20:"PUBBLICAZIONE_188711";s:6:"handle";s:10:"2108/90083";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:87:"New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol";s:9:"metadata6";s:33:"Cazzola, M; Segreti, A; Matera, M";s:9:"metadata7";s:19:"10.2147/DDDT.S39449";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:154;a:14:{s:9:"citazione";s:171:"Cazzola, M., Segreti, A., Calzetta, L., & Rogliani, P. (2013). Comorbidities of asthma. CURRENT OPINION IN PULMONARY MEDICINE, 19(1), 36-41 [10.1097/MCP.0b013e32835b113a].";s:4:"data";s:4:"2013";s:2:"id";s:20:"PUBBLICAZIONE_205016";s:6:"handle";s:10:"2108/97431";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:23:"Comorbidities of asthma";s:9:"metadata6";s:48:"Cazzola, M; Segreti, A; Calzetta, L; Rogliani, P";s:9:"metadata7";s:28:"10.1097/MCP.0b013e32835b113a";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:155;a:14:{s:9:"citazione";s:212:"Segreti, A., Fiori, E., Calzetta, L., Sabatini, M., Segreti, V., Rogliani, P., et al. (2013). The effect of indacaterol during an acute exacerbation of COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 26(6), 630-634.";s:4:"data";s:4:"2013";s:2:"id";s:20:"PUBBLICAZIONE_205012";s:6:"handle";s:10:"2108/97441";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:62:"The effect of indacaterol during an acute exacerbation of COPD";s:9:"metadata6";s:83:"Segreti, A; Fiori, E; Calzetta, L; Sabatini, M; Segreti, V; Rogliani, P; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.pupt.2013.03.020";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:156;a:14:{s:9:"citazione";s:192:"Cazzola, M., Segreti, A., & Rogliani, P. (2012). Comparative effectiveness of drugs for chronic obstructive pulmonary disease. DRUGS OF TODAY, 48(12), 785-794 [10.1358/dot.2012.48.12.1860770].";s:4:"data";s:7:"2012-12";s:2:"id";s:20:"PUBBLICAZIONE_161984";s:6:"handle";s:10:"2108/77850";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:77:"Comparative effectiveness of drugs for chronic obstructive pulmonary disease.";s:9:"metadata6";s:36:"Cazzola, M; Segreti, A; Rogliani, P.";s:9:"metadata7";s:30:"10.1358/dot.2012.48.12.1860770";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:157;a:14:{s:9:"citazione";s:286:"Cazzola, M., Calzetta, L., Rogliani, P., Lauro, D., Novelli, L., Page, C., et al. (2012). High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 47(4), 509-516 [10.1165/rcmb.2011-0449OC].";s:4:"data";s:7:"2012-10";s:2:"id";s:20:"PUBBLICAZIONE_162020";s:6:"handle";s:10:"2108/77990";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:93:"High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway.";s:9:"metadata6";s:91:"Cazzola, M; Calzetta, L; Rogliani, P; Lauro, D; Novelli, L; Page, C; Kanabar, V; Matera, Mg";s:9:"metadata7";s:24:"10.1165/rcmb.2011-0449OC";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:158;a:14:{s:9:"citazione";s:186:"Cazzola, M., Rogliani, P., Segreti, A., & Matera, M.G. (2012). An update on bronchodilators in Phase I and II clinical trials. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 21(10), 1489-1501.";s:4:"data";s:7:"2012-10";s:2:"id";s:20:"PUBBLICAZIONE_162022";s:6:"handle";s:10:"2108/78016";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:62:"An update on bronchodilators in Phase I and II clinical trials";s:9:"metadata6";s:47:"Cazzola, M; Rogliani, P; Segreti, A; Matera, MG";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:159;a:14:{s:9:"citazione";s:183:"Cazzola, M., Page, C.P., Calzetta, L., & Matera, M.G. (2012). Emerging anti-inflammatory strategies for COPD. EUROPEAN RESPIRATORY JOURNAL, 40(3), 724-741 [10.1183/09031936.00213711].";s:4:"data";s:7:"2012-09";s:2:"id";s:20:"PUBBLICAZIONE_162468";s:6:"handle";s:10:"2108/78114";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:46:"Emerging anti-inflammatory strategies for COPD";s:9:"metadata6";s:45:"Cazzola, M; Page, CP; Calzetta, L; Matera, MG";s:9:"metadata7";s:25:"10.1183/09031936.00213711";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:160;a:14:{s:9:"citazione";s:236:"Cazzola, M., Capuano, A., Rogliani, P., & Matera, M.C. (2012). Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. CURRENT OPINION IN PHARMACOLOGY, 12(3), 300-308 [10.1016/j.coph.2012.01.019].";s:4:"data";s:7:"2012-06";s:2:"id";s:20:"PUBBLICAZIONE_162048";s:6:"handle";s:10:"2108/78020";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:95:"Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD.";s:9:"metadata6";s:54:"Cazzola, M; Capuano, A; Rogliani, P; Matera, MG. Curr";s:9:"metadata7";s:26:"10.1016/j.coph.2012.01.019";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:161;a:14:{s:9:"citazione";s:176:"Cazzola, M., Page, C.P., Calzetta, L., & Matera, M.G. (2012). Pharmacology and therapeutics of bronchodilators. PHARMACOLOGICAL REVIEWS, 64(3), 450-504 [10.1124/pr.111.004580].";s:4:"data";s:7:"2012-06";s:2:"id";s:20:"PUBBLICAZIONE_162439";s:6:"handle";s:10:"2108/78129";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:48:"Pharmacology and therapeutics of bronchodilators";s:9:"metadata6";s:45:"Cazzola, M; Page, CP; Calzetta, L; Matera, MG";s:9:"metadata7";s:21:"10.1124/pr.111.004580";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:162;a:14:{s:9:"citazione";s:189:"Matera, M.G., & Cazzola, M. (2012). Treatment of COPD: no longer nihilism, but there is still an urgent need for new therapies. CURRENT OPINION IN PHARMACOLOGY [10.1016/j.coph.2012.03.006].";s:4:"data";s:7:"2012-06";s:2:"id";s:20:"PUBBLICAZIONE_162572";s:6:"handle";s:10:"2108/78158";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:91:"Treatment of COPD: no longer nihilism, but there is still an urgent need for new therapies.";s:9:"metadata6";s:23:"Matera, MG; Cazzola, M.";s:9:"metadata7";s:26:"10.1016/j.coph.2012.03.006";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:163;a:14:{s:9:"citazione";s:168:"Matera, M.G., Calzetta, L., Rinaldi, B., & Cazzola, M. (2012). Treatment of COPD: moving beyond the lungs. CURRENT OPINION IN PHARMACOLOGY [10.1016/j.coph.2012.04.001].";s:4:"data";s:7:"2012-06";s:2:"id";s:20:"PUBBLICAZIONE_162569";s:6:"handle";s:10:"2108/78159";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:43:"Treatment of COPD: moving beyond the lungs.";s:9:"metadata6";s:48:"Matera, MG; Calzetta, L; Rinaldi, B; Cazzola, M.";s:9:"metadata7";s:26:"10.1016/j.coph.2012.04.001";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:164;a:14:{s:9:"citazione";s:199:"Cazzola, M., & Matera, M.G. (2012). Lung blood flow must be considered when prescribing a long-acting β2-agonist/inhaled corticosteroid combination. CHEST, 141(5), 1134-1136 [10.1378/chest.11-2497].";s:4:"data";s:7:"2012-05";s:2:"id";s:20:"PUBBLICAZIONE_162518";s:6:"handle";s:10:"2108/78009";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:112:"Lung blood flow must be considered when prescribing a long-acting β2-agonist/inhaled corticosteroid combination";s:9:"metadata6";s:22:"Cazzola, M; Matera, MG";s:9:"metadata7";s:21:"10.1378/chest.11-2497";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:165;a:14:{s:9:"citazione";s:156:"Cazzola, M., & Matera, M.G. (2012). IL-17 in chronic obstructive pulmonary disease. EXPERT REVIEW OF RESPIRATORY MEDICINE, 6(2), 135-138 [10.1586/ers.12.7].";s:4:"data";s:7:"2012-04";s:2:"id";s:20:"PUBBLICAZIONE_162524";s:6:"handle";s:10:"2108/78135";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:47:"IL-17 in chronic obstructive pulmonary disease.";s:9:"metadata6";s:22:"Cazzola, M; Matera, MG";s:9:"metadata7";s:16:"10.1586/ers.12.7";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:166;a:14:{s:9:"citazione";s:346:"Cazzola, M., Paggiaro, P., Palange, P., Bjermer, L., Ausin, P., Carlsson, L.G., et al. (2012). Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study. CLINICAL DRUG INVESTIGATION [10.2165/11630880-000000000-00000].";s:4:"data";s:7:"2012-03";s:2:"id";s:20:"PUBBLICAZIONE_162564";s:6:"handle";s:10:"2108/78156";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:187:"Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.";s:9:"metadata6";s:96:"Cazzola, M; Paggiaro, P; Palange, P; Bjermer, L; Ausin, P; Carlsson, LG; Ekelund, J; Lotvall, J.";s:9:"metadata7";s:32:"10.2165/11630880-000000000-00000";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:167;a:14:{s:9:"citazione";s:199:"Matera, M.G., Calzetta, L., Segreti, A., & Cazzola, M. (2012). Emerging drugs for chronic obstructive pulmonary disease. EXPERT OPINION ON EMERGING DRUGS, 17(1), 61-82 [10.1517/14728214.2012.660917].";s:4:"data";s:7:"2012-03";s:2:"id";s:20:"PUBBLICAZIONE_162487";s:6:"handle";s:10:"2108/78121";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:57:"Emerging drugs for chronic obstructive pulmonary disease.";s:9:"metadata6";s:48:"Matera, MG; Calzetta, L; Segreti, A; Cazzola, M.";s:9:"metadata7";s:28:"10.1517/14728214.2012.660917";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:168;a:14:{s:9:"citazione";s:191:"van der Molen, T., & Cazzola, M. (2012). Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. PRIMARY CARE RESPIRATORY JOURNAL.";s:4:"data";s:7:"2012-03";s:2:"id";s:20:"PUBBLICAZIONE_162559";s:6:"handle";s:10:"2108/78155";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:116:"Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes.";s:9:"metadata6";s:29:"van der Molen, T; Cazzola, M.";s:9:"metadata7";s:23:"10.4104/pcrj.2011.00102";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:169;a:14:{s:9:"citazione";s:182:"Cazzola, M., & Matera, M.G. (2012). Tremor and β2-adrenergic agents: is it a real clinical problem?. PULMONARY PHARMACOLOGY & THERAPEUTICS, 25(1), 4-10 [10.1016/j.pupt.2011.12.004].";s:4:"data";s:7:"2012-02";s:2:"id";s:20:"PUBBLICAZIONE_162478";s:6:"handle";s:10:"2108/78134";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:64:"Tremor and β2-adrenergic agents: is it a real clinical problem?";s:9:"metadata6";s:22:"Cazzola, M; Matera, MG";s:9:"metadata7";s:26:"10.1016/j.pupt.2011.12.004";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:170;a:14:{s:9:"citazione";s:262:"Cazzola, M., Calzetta, L., Bettoncelli, G., Cricelli, C., Romeo, F., Matera, M., et al. (2012). Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. RESPIRATORY MEDICINE, 106(2), 249-256 [10.1016/j.rmed.2011.07.021].";s:4:"data";s:7:"2012-02";s:2:"id";s:19:"PUBBLICAZIONE_88540";s:6:"handle";s:10:"2108/52355";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:97:"Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study";s:9:"metadata6";s:86:"Cazzola, M; Calzetta, L; Bettoncelli, G; Cricelli, C; Romeo, F; Matera, M; Rogliani, P";s:9:"metadata7";s:26:"10.1016/j.rmed.2011.07.021";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:171;a:14:{s:9:"citazione";s:256:"Rossi, A., Centanni, S., Cerveri, I., Gulotta, C., Foresi, A., Cazzola, M., et al. (2012). Acute effects of indacaterol on lung hyperinflation in moderate COPD: A comparison with tiotropium. RESPIRATORY MEDICINE, 106(1), 84-90 [10.1016/j.rmed.2011.09.006].";s:4:"data";s:7:"2012-01";s:2:"id";s:19:"PUBBLICAZIONE_88535";s:6:"handle";s:10:"2108/52353";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:98:"Acute effects of indacaterol on lung hyperinflation in moderate COPD: A comparison with tiotropium";s:9:"metadata6";s:81:"Rossi, A; Centanni, S; Cerveri, I; Gulotta, C; Foresi, A; Cazzola, M; Brusasco, V";s:9:"metadata7";s:26:"10.1016/j.rmed.2011.09.006";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:172;a:14:{s:9:"citazione";s:250:"Hewson, C., Patel, S., Calzetta, L., Campwala, H., Havard, S., Luscombe, E., et al. (2011). Preclinical evaluation of an inhibitor of cytosolic phospholipase A2α for the treatment of asthma. THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS.";s:4:"data";s:10:"2011-12-09";s:2:"id";s:19:"PUBBLICAZIONE_88539";s:6:"handle";s:10:"2108/52357";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:98:"Preclinical evaluation of an inhibitor of cytosolic phospholipase A2α for the treatment of asthma";s:9:"metadata6";s:190:"Hewson, C; Patel, S; Calzetta, L; Campwala, H; Havard, S; Luscombe, E; Clarke, P; Peachell, P; Matera, M; Cazzola, M; Page, C; Abraham, W; Williams, C; Clark, J; Liu, W; Clarke, N; Yeadon, M";s:9:"metadata7";s:23:"10.1124/jpet.111.186379";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:173;a:14:{s:9:"citazione";s:250:"Calzetta, L., Spina, D., Cazzola, M., Page, C., Facciolo, F., Rendina, E., et al. (2011). Pharmacological characterization of adenosine receptors on isolated human bronchi. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 45(6), 1222-1231.";s:4:"data";s:7:"2011-12";s:2:"id";s:19:"PUBBLICAZIONE_88537";s:6:"handle";s:10:"2108/52348";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:81:"Pharmacological characterization of adenosine receptors on isolated human bronchi";s:9:"metadata6";s:78:"Calzetta, L; Spina, D; Cazzola, M; Page, C; Facciolo, F; Rendina, E; Matera, M";s:9:"metadata7";s:24:"10.1165/rcmb.2011-0056OC";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:174;a:14:{s:9:"citazione";s:197:"Cazzola, M., Anapurapu, S., & Page, C. (2011). Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: A meta-analysis. PULMONARY PHARMACOLOGY & THERAPEUTICS.";s:4:"data";s:10:"2011-11-27";s:2:"id";s:19:"PUBBLICAZIONE_88536";s:6:"handle";s:10:"2108/52359";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:110:"Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: A meta-analysis";s:9:"metadata6";s:33:"Cazzola, M; Anapurapu, S; Page, C";s:9:"metadata7";s:26:"10.1016/j.pupt.2011.11.002";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:175;a:14:{s:9:"citazione";s:175:"Cazzola, M., & Matera, M. (2011). Inhibiting or blocking LIGHT, a TNF superfamily member, for treating airway remodeling. EXPERT REVIEW OF RESPIRATORY MEDICINE, 5(5), 623-625.";s:4:"data";s:7:"2011-10";s:2:"id";s:19:"PUBBLICAZIONE_88541";s:6:"handle";s:10:"2108/52356";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:86:"Inhibiting or blocking LIGHT, a TNF superfamily member, for treating airway remodeling";s:9:"metadata6";s:21:"Cazzola, M; Matera, M";s:9:"metadata7";s:17:"10.1586/ers.11.65";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:176;a:14:{s:9:"citazione";s:265:"Cazzola, M., Calzetta, L., Page, C., Rinaldi, B., Capuano, A., & Matera, M. (2011). Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 45(4), 704-710.";s:4:"data";s:7:"2011-10";s:2:"id";s:19:"PUBBLICAZIONE_88533";s:6:"handle";s:10:"2108/52351";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:104:"Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi";s:9:"metadata6";s:67:"Cazzola, M; Calzetta, L; Page, C; Rinaldi, B; Capuano, A; Matera, M";s:9:"metadata7";s:24:"10.1165/rcmb.2010-0306OC";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:177;a:14:{s:9:"citazione";s:241:"Cazzola, M., Segreti, A., Bettoncelli, G., Calzetta, L., Cricelli, C., Pasqua, F., et al. (2011). Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. PRIMARY CARE RESPIRATORY JOURNAL, 20(3), 291-298.";s:4:"data";s:10:"2011-09-20";s:2:"id";s:19:"PUBBLICAZIONE_87975";s:6:"handle";s:10:"2108/42187";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:92:"Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008";s:9:"metadata6";s:88:"Cazzola, M; Segreti, A; Bettoncelli, G; Calzetta, L; Cricelli, C; Pasqua, F; Rogliani, P";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:178;a:14:{s:9:"citazione";s:239:"Agusti, A., Hedner, J., Marin, J., Barbé, F., Cazzola, M., & Rennard, S. (2011). Night-time symptoms: a forgotten dimension of COPD. European respiratory review : an official journal of the European Respiratory Society, 20(121), 183-194.";s:4:"data";s:10:"2011-09-01";s:2:"id";s:19:"PUBBLICAZIONE_88538";s:6:"handle";s:10:"2108/52360";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:50:"Night-time symptoms: a forgotten dimension of COPD";s:9:"metadata6";s:66:"Agusti, A; Hedner, J; Marin, J; Barbé, F; Cazzola, M; Rennard, S";s:9:"metadata7";s:25:"10.1183/09059180.00004311";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:179;a:14:{s:9:"citazione";s:241:"Cazzola, M., Segreti, A., Bettoncelli, G., Calzetta, L., Cricelli, C., Pasqua, F., et al. (2011). Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. PRIMARY CARE RESPIRATORY JOURNAL, 20(3), 291-298.";s:4:"data";s:7:"2011-09";s:2:"id";s:19:"PUBBLICAZIONE_88542";s:6:"handle";s:10:"2108/40452";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:92:"Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008";s:9:"metadata6";s:88:"Cazzola, M; Segreti, A; Bettoncelli, G; Calzetta, L; Cricelli, C; Pasqua, F; Rogliani, P";s:9:"metadata7";s:23:"10.4104/pcrj.2011.00033";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:180;a:14:{s:9:"citazione";s:218:"Cazzola, M., Calzetta, L., Bettoncelli, G., Cricelli, C., Romeo, F., Matera, M.G., et al. (2011). Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. RESPIRATORY MEDICINE.";s:4:"data";s:10:"2011-08-17";s:2:"id";s:19:"PUBBLICAZIONE_87973";s:6:"handle";s:10:"2108/52663";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:97:"Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study";s:9:"metadata6";s:87:"Cazzola, M; Calzetta, L; Bettoncelli, G; Cricelli, C; Romeo, F; Matera, MG; Rogliani, P";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:181;a:14:{s:9:"citazione";s:291:"Matera, M., Calzetta, L., Passeri, D., Facciolo, F., Rendina, E., Page, C., et al. (2011). Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi. BRITISH JOURNAL OF PHARMACOLOGY, 163(8), 1740-1754 [10.1111/j.1476-5381.2011.01339.x].";s:4:"data";s:7:"2011-08";s:2:"id";s:19:"PUBBLICAZIONE_88534";s:6:"handle";s:10:"2108/52352";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:112:"Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi";s:9:"metadata6";s:92:"Matera, M; Calzetta, L; Passeri, D; Facciolo, F; Rendina, E; Page, C; Cazzola, M; Orlandi, A";s:9:"metadata7";s:32:"10.1111/j.1476-5381.2011.01339.x";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:182;a:14:{s:9:"citazione";s:177:"Matera, M., Page, C., & Cazzola, M. (2011). Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. TRENDS IN PHARMACOLOGICAL SCIENCES, 32(8), 495-506.";s:4:"data";s:7:"2011-08";s:2:"id";s:19:"PUBBLICAZIONE_88532";s:6:"handle";s:10:"2108/52362";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:80:"Novel bronchodilators for the treatment of chronic obstructive pulmonary disease";s:9:"metadata6";s:30:"Matera, M; Page, C; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.tips.2011.04.003";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:183;a:14:{s:9:"citazione";s:202:"Cazzola, M., Calzetta, L., Bettoncelli, G., Novelli, L., Cricelli, C., & Rogliani, P. (2011). Asthma and comorbid medical illness. EUROPEAN RESPIRATORY JOURNAL, 38(1), 42-49 [10.1183/09031936.00140310].";s:4:"data";s:7:"2011-07";s:2:"id";s:20:"PUBBLICAZIONE_209419";s:6:"handle";s:11:"2108/115053";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:36:"Asthma and comorbid medical illness.";s:9:"metadata6";s:77:"Cazzola, M; Calzetta, L; Bettoncelli, G; Novelli, L; Cricelli, C; Rogliani, P";s:9:"metadata7";s:25:"10.1183/09031936.00140310";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:184;a:14:{s:9:"citazione";s:202:"Cazzola, M., Calzetta, L., Bettoncelli, G., Novelli, L., Cricelli, C., & Rogliani, P. (2011). Asthma and comorbid medical illness. EUROPEAN RESPIRATORY JOURNAL, 38(1), 42-49 [10.1183/09031936.00140310].";s:4:"data";s:7:"2011-07";s:2:"id";s:19:"PUBBLICAZIONE_87976";s:6:"handle";s:10:"2108/29563";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:35:"Asthma and comorbid medical illness";s:9:"metadata6";s:77:"Cazzola, M; Calzetta, L; Bettoncelli, G; Novelli, L; Cricelli, C; Rogliani, P";s:9:"metadata7";s:25:"10.1183/09031936.00140310";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:185;a:14:{s:9:"citazione";s:154:"Cazzola, M., Calzetta, L., & Matera, M. (2011). β(2) -adrenoceptor agonists: current and future direction. BRITISH JOURNAL OF PHARMACOLOGY, 163(1), 4-17.";s:4:"data";s:7:"2011-05";s:2:"id";s:19:"PUBBLICAZIONE_88549";s:6:"handle";s:10:"2108/52367";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:58:"β(2) -adrenoceptor agonists: current and future direction";s:9:"metadata6";s:34:"Cazzola, M; Calzetta, L; Matera, M";s:9:"metadata7";s:32:"10.1111/j.1476-5381.2011.01216.x";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:186;a:14:{s:9:"citazione";s:235:"Matera, M., Calzetta, L., Rogliani, P., Bardaro, F., Page, C., & Cazzola, M. (2011). Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. PULMONARY PHARMACOLOGY & THERAPEUTICS, 24(2), 221-226.";s:4:"data";s:7:"2011-04";s:2:"id";s:19:"PUBBLICAZIONE_88552";s:6:"handle";s:10:"2108/52366";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:94:"Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi";s:9:"metadata6";s:68:"Matera, M; Calzetta, L; Rogliani, P; Bardaro, F; Page, C; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.pupt.2010.12.008";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:187;a:14:{s:9:"citazione";s:233:"Cazzola, M., Puxeddu, E., Bettoncelli, G., Novelli, L., Segreti, A., Cricelli, C., et al. (2011). The prevalence of asthma and COPD in Italy: a practice-based study. RESPIRATORY MEDICINE, 105(3), 386-391 [10.1016/j.rmed.2010.09.022].";s:4:"data";s:7:"2011-03";s:2:"id";s:19:"PUBBLICAZIONE_88551";s:6:"handle";s:10:"2108/52368";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:66:"The prevalence of asthma and COPD in Italy: a practice-based study";s:9:"metadata6";s:88:"Cazzola, M; Puxeddu, E; Bettoncelli, G; Novelli, L; Segreti, A; Cricelli, C; Calzetta, L";s:9:"metadata7";s:26:"10.1016/j.rmed.2010.09.022";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:188;a:14:{s:9:"citazione";s:318:"Kessler, R., Partridge, M., Miravitlles, M., Cazzola, M., Vogelmeier, C., Leynaud, D., et al. (2011). Symptom variability in patients with severe COPD: a pan-European cross-sectional study. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology, 37(2), 264-272.";s:4:"data";s:7:"2011-02";s:2:"id";s:19:"PUBBLICAZIONE_88550";s:6:"handle";s:10:"2108/52369";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:86:"Symptom variability in patients with severe COPD: a pan-European cross-sectional study";s:9:"metadata6";s:93:"Kessler, R; Partridge, M; Miravitlles, M; Cazzola, M; Vogelmeier, C; Leynaud, D; Ostinelli, J";s:9:"metadata7";s:25:"10.1183/09031936.00051110";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:189;a:14:{s:9:"citazione";s:138:"Cazzola, M., & Novelli, G. (2010). Biomarkers in COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 23(6), 493-500 [10.1016/j.pupt.2010.05.001].";s:4:"data";s:7:"2010-12";s:2:"id";s:19:"PUBBLICAZIONE_41588";s:6:"handle";s:10:"2108/13189";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:32:"Settore MED/03 - Genetica Medica";s:9:"metadata4";N;s:9:"metadata5";s:18:"Biomarkers in COPD";s:9:"metadata6";s:22:"Cazzola, M; Novelli, G";s:9:"metadata7";s:26:"10.1016/j.pupt.2010.05.001";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:190;a:14:{s:9:"citazione";s:207:"Rogliani, P., Curradi, G., Mura, M., Lauro, D., Federici, M., Galli, A., et al. (2010). Metabolic syndrome and risk of pulmonary involvement. RESPIRATORY MEDICINE, 104(1), 47-51 [10.1016/j.rmed.2009.08.009].";s:4:"data";s:7:"2010-01";s:2:"id";s:19:"PUBBLICAZIONE_88838";s:6:"handle";s:10:"2108/29796";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:52:"Metabolic syndrome and risk of pulmonary involvement";s:9:"metadata6";s:89:"Rogliani, P; Curradi, G; Mura, M; Lauro, D; Federici, M; Galli, A; Saltini, C; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.rmed.2009.08.009";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:191;a:14:{s:9:"citazione";s:187:"Capuano, R., Santonico, M., Martinelli, E., Pennazza, G., Paolesse, R., Bergamini, A., et al. (2010). COPD diagnosis by a gas sensor array. In Procedia engineering (pp.484-487). Elsevier.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_34531";s:6:"handle";s:9:"2108/8586";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:32:"Settore ING-INF/01 - Elettronica";s:9:"metadata4";N;s:9:"metadata5";s:36:"COPD diagnosis by a gas sensor array";s:9:"metadata6";s:130:"Capuano, R; Santonico, M; Martinelli, E; Pennazza, G; Paolesse, R; Bergamini, A; Cazzola, M; Ciaprini, C; Di Natale, C; D'Amico, A";s:9:"metadata7";s:28:"10.1016/j.proeng.2010.09.152";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:192;a:14:{s:9:"citazione";s:230:"Cazzola, M. (2010). The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 4(4), 195-198.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35787";s:6:"handle";s:10:"2108/42041";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:150:"The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease.";s:9:"metadata6";s:11:"Cazzola, M.";s:9:"metadata7";s:24:"10.1177/1753465810377636";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:193;a:14:{s:9:"citazione";s:192:"Cazzola, M., & Molimard, M. (2010). The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 23(4), 257-267.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35780";s:6:"handle";s:10:"2108/42042";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:101:"The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.";s:9:"metadata6";s:23:"Cazzola, M; Molimard, M";s:9:"metadata7";s:26:"10.1016/j.pupt.2010.03.003";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:194;a:14:{s:9:"citazione";s:180:"Cazzola, M., Bettoncelli, G., Sessa, E., Cricelli, & C, B. (2010). Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. RESPIRATION, 80(2), 112-119.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35652";s:6:"handle";s:10:"2108/42083";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:83:"Prevalence of comorbidities in patients with chronic obstructive pulmonary disease.";s:9:"metadata6";s:63:"Cazzola, M; Bettoncelli, G; Sessa, E; Cricelli; C, Biscione, G.";s:9:"metadata7";s:17:"10.1159/000281880";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:195;a:14:{s:9:"citazione";s:147:"Cazzola, M., Calzetta, L., & Matera, M.G. (2010). The cardiovascular risk of tiotropium: is it real?. EXPERT OPINION ON DRUG SAFETY, 9(5), 783-792.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35502";s:6:"handle";s:10:"2108/42098";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:50:"The cardiovascular risk of tiotropium: is it real?";s:9:"metadata6";s:35:"Cazzola, M; Calzetta, L; Matera, MG";s:9:"metadata7";s:28:"10.1517/14740338.2010.500611";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:196;a:14:{s:9:"citazione";s:188:"Cazzola, M., Camiciottoli, G., Bonavia, M., Gulotta, C., Ravazzi, A., Alessandrini, A., et al. (2010). Italian real-life experience of omalizumab. RESPIRATORY MEDICINE, 104(10), 1410-1416.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35541";s:6:"handle";s:10:"2108/42101";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:42:"Italian real-life experience of omalizumab";s:9:"metadata6";s:192:"Cazzola, M; Camiciottoli, G; Bonavia, M; Gulotta, C; Ravazzi, A; Alessandrini, A; Caiaffa, MF; Berra, A; Schino, P; Di Napoli, PL; Maselli, R; Pelaia, G; Bucchioni, E; Paggiaro, PL; Macchia, L";s:9:"metadata7";s:26:"10.1016/j.rmed.2010.04.013";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:197;a:14:{s:9:"citazione";s:237:"Cazzola, M., Floriani, I., & Page, C.P. (2010). The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. PULMONARY PHARMACOLOGY & THERAPEUTICS, 23(2), 135-144.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35579";s:6:"handle";s:10:"2108/42084";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:134:"The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.";s:9:"metadata6";s:33:"Cazzola, M; Floriani, I; Page, CP";s:9:"metadata7";s:26:"10.1016/j.pupt.2009.10.002";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:198;a:14:{s:9:"citazione";s:152:"Cazzola, M., Hanania, N.A., & Matera, M.G. (2010). Arformoterol tartrate in the treatment of COPD. EXPERT REVIEW OF RESPIRATORY MEDICINE, 4(2), 155-162.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35785";s:6:"handle";s:10:"2108/42060";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:47:"Arformoterol tartrate in the treatment of COPD.";s:9:"metadata6";s:35:"Cazzola, M; Hanania, NA; Matera, MG";s:9:"metadata7";s:17:"10.1586/ers.10.16";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:199;a:14:{s:9:"citazione";s:303:"Cazzola, M., Pasqua, F., Ferri, L., Biscione, G., Cardaci, V., & Matera, M.G. (2010). Rapid onset of bronchodilation with formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler as compared to formoterol alone in patients with COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 24(1), 118-122.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35457";s:6:"handle";s:10:"2108/42092";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:161:"Rapid onset of bronchodilation with formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler as compared to formoterol alone in patients with COPD";s:9:"metadata6";s:68:"Cazzola, M; Pasqua, F; Ferri, L; Biscione, G; Cardaci, V; Matera, MG";s:9:"metadata7";s:26:"10.1016/j.pupt.2010.08.005";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:200;a:14:{s:9:"citazione";s:293:"Cazzola, M., Pham-Thi, N., Kerihuel, J.C., Durand, H., & Bohbot, S. (2010). Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study. Therapeutic Advances in Respiratory Diseases, 4(5), 271-278.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35774";s:6:"handle";s:10:"2108/42087";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:156:"Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study.";s:9:"metadata6";s:59:"Cazzola, M; Pham-Thi, N; Kerihuel, JC; Durand, H; Bohbot, S";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:201;a:14:{s:9:"citazione";s:182:"Cazzola, M., Picciolo, S., & Matera, M.G. (2010). Roflumilast in chronic obstructive pulmonary disease: evidence from large trials. EXPERT OPINION ON PHARMACOTHERAPY, 11(3), 441-449.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35575";s:6:"handle";s:10:"2108/42094";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:81:"Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.";s:9:"metadata6";s:35:"Cazzola, M; Picciolo, S; Matera, MG";s:9:"metadata7";s:25:"10.1517/14656560903555201";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:202;a:14:{s:9:"citazione";s:143:"Cazzola, M., Proietto, A., & Matera, M.G. (2010). Indacaterol for chronic obstructive pulmonary disease (COPD). DRUGS OF TODAY, 46(3), 139-150.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35778";s:6:"handle";s:10:"2108/42063";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:61:"Indacaterol for chronic obstructive pulmonary disease (COPD).";s:9:"metadata6";s:35:"Cazzola, M; Proietto, A; Matera, MG";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:203;a:14:{s:9:"citazione";s:133:"Cazzola, M., Segreti, A., & Matera, M.G. (2010). Novel bronchodilators in asthma. CURRENT OPINION IN PULMONARY MEDICINE, 16(1), 6-12.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35578";s:6:"handle";s:10:"2108/42070";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:32:"Novel bronchodilators in asthma.";s:9:"metadata6";s:34:"Cazzola, M; Segreti, A; Matera, MG";s:9:"metadata7";s:28:"10.1097/MCP.0b013e32833303d2";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:204;a:14:{s:9:"citazione";s:197:"Cazzola, M., Segreti, A., Stirpe, E., Appodia, M., Senis, L., & Matera, M.G. (2010). Energy expenditure and impact of bronchodilators in COPD patients. RESPIRATORY MEDICINE CME, 104(10), 1490-1494.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35564";s:6:"handle";s:10:"2108/42097";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:66:"Energy expenditure and impact of bronchodilators in COPD patients.";s:9:"metadata6";s:67:"Cazzola, M; Segreti, A; Stirpe, E; Appodia, M; Senis, L; Matera, MG";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:205;a:14:{s:9:"citazione";s:190:"Cazzola, M., Tompkins, T.A., & Matera, M.G. (2010). Immunomodulatory impact of a synbiotic in T(h)1 and T(h)2 models of infection. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 4(5), 259-270.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35772";s:6:"handle";s:10:"2108/42091";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:78:"Immunomodulatory impact of a synbiotic in T(h)1 and T(h)2 models of infection.";s:9:"metadata6";s:36:"Cazzola, M; Tompkins, TA; Matera, MG";s:9:"metadata7";s:24:"10.1177/1753465810379009";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:206;a:14:{s:9:"citazione";s:268:"Di Marco, F., Guazzi, M., Vicenzi, M., Santus, P., Cazzola, M., Pappalettera, M., et al. (2010). Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: A pilot study. PULMONARY PHARMACOLOGY & THERAPEUTICS, 23(3), 159-164.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35790";s:6:"handle";s:10:"2108/42039";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:116:"Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: A pilot study.";s:9:"metadata6";s:103:"Di Marco, F; Guazzi, M; Vicenzi, M; Santus, P; Cazzola, M; Pappalettera, M; Castellotti, P; Centanni, S";s:9:"metadata7";s:26:"10.1016/j.pupt.2010.01.004";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:207;a:14:{s:9:"citazione";s:325:"Gallelli, L., Pelaia, G., Fratto, D., Muto, V., Falcone, D., Vatrella, A., et al. (2010). Effects of budesonide on P38 MAPK activation, apoptosis and IL-8 secretion, induced by TNF-alpha and Haemophilus influenzae in human bronchial epithelial cells. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 23(2), 471-479.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35788";s:6:"handle";s:10:"2108/42040";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:160:"Effects of budesonide on P38 MAPK activation, apoptosis and IL-8 secretion, induced by TNF-alpha and Haemophilus influenzae in human bronchial epithelial cells.";s:9:"metadata6";s:163:"Gallelli, L; Pelaia, G; Fratto, D; Muto, V; Falcone, D; Vatrella, A; Curto, LS; Renda, T; Busceti, MT; Liberto, MC; Savino, R; Cazzola, M; Marsico, SA; Maselli, R.";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:208;a:14:{s:9:"citazione";s:197:"Matera, M.G., Calzetta, L., & Cazzola, M. (2010). TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. PULMONARY PHARMACOLOGY & THERAPEUTICS, 23(2), 121-128.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35786";s:6:"handle";s:10:"2108/42036";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:92:"TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water.";s:9:"metadata6";s:35:"Matera, MG; Calzetta, L; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.pupt.2009.10.007";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:209;a:14:{s:9:"citazione";s:253:"Matera, M.G., Martuscelli, E., & Cazzola, M. (2010). Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. PULMONARY PHARMACOLOGY & THERAPEUTICS, 23(1), 1-8.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35653";s:6:"handle";s:10:"2108/42104";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:148:"Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure";s:9:"metadata6";s:39:"Matera, MG; Martuscelli, E; Cazzola, M.";s:9:"metadata7";s:26:"10.1016/j.pupt.2009.10.001";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:210;a:14:{s:9:"citazione";s:213:"Pasqua, F., Biscione, G., Crigna, G., Auciello, L., & Cazzola, M. (2010). Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot study. RESPIRATORY MEDICINE, 104(3), 412-417.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35791";s:6:"handle";s:10:"2108/42033";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:100:"Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot study.";s:9:"metadata6";s:58:"Pasqua, F; Biscione, G; Crigna, G; Auciello, L; Cazzola, M";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:211;a:14:{s:9:"citazione";s:285:"Tannu, S.A., Renzetti, L.M., Tare, N., Ventre, J.D., Lavelle, D., Lin, T.A., et al. (2010). Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors. BRITISH JOURNAL OF PHARMACOLOGY, 161(6), 1329-1342.";s:4:"data";s:4:"2010";s:2:"id";s:19:"PUBBLICAZIONE_35463";s:6:"handle";s:10:"2108/42100";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:140:"Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors";s:9:"metadata6";s:212:"Tannu, SA; Renzetti, LM; Tare, N; Ventre, JD; Lavelle, D; Lin, TA; Morschauser, A; Paciorek, J; Bolin, DR; Michel, H; Singer, L; Hargaden, M; Knowles, I; Gardiner, P; Cazzola, M; Calzetta, L; Matera, MG; Hicks, A";s:9:"metadata7";s:31:"0.1111/j.1476-5381.2010.00975.x";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:212;a:14:{s:9:"citazione";s:148:"Cazzola, M., & Tashkin, D. (2009). Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD, 6(5), 404-415.";s:4:"data";s:7:"2009-10";s:2:"id";s:20:"PUBBLICAZIONE_210931";s:6:"handle";s:11:"2108/105928";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:91:"Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function";s:9:"metadata6";s:22:"Cazzola, M; Tashkin, D";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:213;a:14:{s:9:"citazione";s:168:"Cazzola M. (2009). Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 10(5), 482-490.";s:4:"data";s:4:"2009";s:2:"id";s:19:"PUBBLICAZIONE_13944";s:6:"handle";s:10:"2108/42118";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:90:"Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD";s:9:"metadata6";s:10:"Cazzola M.";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:214;a:14:{s:9:"citazione";s:144:"Cazzola M., B.G. (2009). Primary care of the patient with chronic obstructive pulmonary disease in Italy. RESPIRATORY MEDICINE, 103(4), 582-588.";s:4:"data";s:4:"2009";s:2:"id";s:19:"PUBBLICAZIONE_19900";s:6:"handle";s:10:"2108/42111";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:79:"Primary care of the patient with chronic obstructive pulmonary disease in Italy";s:9:"metadata6";s:49:"Cazzola M., Bettoncelli G., Sessa E., Cricelli C.";s:9:"metadata7";s:26:"10.1016/j.rmed.2008.10.017";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:215;a:14:{s:9:"citazione";s:175:"Cazzola, M. (2009). Diagnostic approach: clinical implications of the new experimental evidence. In MULTIDISCIPLINARY RESPIRATORY MEDICINE (pp.55-56). BORGOMANERO : NOVAMEDIA.";s:4:"data";s:4:"2009";s:2:"id";s:19:"PUBBLICAZIONE_12574";s:6:"handle";s:10:"2108/42120";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:75:"Diagnostic approach: clinical implications of the new experimental evidence";s:9:"metadata6";s:10:"Cazzola, M";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:216;a:14:{s:9:"citazione";s:165:"Cazzola, M. (2009). Pharmacology of the small airways [Farmacologia delle piccole vie aeree]. RASSEGNA DI PATOLOGIA DELL’APPARATO RESPIRATORIO, 24(1, S. 1), 19-26.";s:4:"data";s:4:"2009";s:2:"id";s:18:"PUBBLICAZIONE_5192";s:6:"handle";s:10:"2108/42136";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:72:"Pharmacology of the small airways [Farmacologia delle piccole vie aeree]";s:9:"metadata6";s:10:"Cazzola, M";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:217;a:14:{s:9:"citazione";s:220:"Cazzola, M., Mura, M., Segreti, A., Mattei, M.A., & Rogliani, P. (2009). Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: Forme-fruste of Churg-Strauss syndrome?. ALLERGY, 64(9), 1389-1390.";s:4:"data";s:4:"2009";s:2:"id";s:18:"PUBBLICAZIONE_4700";s:6:"handle";s:10:"2108/42127";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:119:"Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: Forme-fruste of Churg-Strauss syndrome?";s:9:"metadata6";s:56:"Cazzola, M; Mura, M; Segreti, A; Mattei, MA; Rogliani, P";s:9:"metadata7";s:32:"10.1111/j.1398-9995.2009.02061.x";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:218;a:14:{s:9:"citazione";s:272:"Cazzola, M., Noschese, P., & Di Perna, F. (2009). Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 3(2), 59-63 [10.1177/1753465809104677].";s:4:"data";s:4:"2009";s:2:"id";s:18:"PUBBLICAZIONE_4826";s:6:"handle";s:10:"2108/42131";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:136:"Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone";s:9:"metadata6";s:36:"Cazzola, M; Noschese, P; Di Perna, F";s:9:"metadata7";s:24:"10.1177/1753465809104677";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:219;a:14:{s:9:"citazione";s:335:"Cazzola, M., Rogliani, P., Curradi, G., Segreti, A., Ciaprini, C., Pezzuto, G., et al. (2009). A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 22(6), 522-525 [10.1016/j.pupt.2009.05.005].";s:4:"data";s:4:"2009";s:2:"id";s:20:"PUBBLICAZIONE_205015";s:6:"handle";s:10:"2108/97438";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:155:"A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD";s:9:"metadata6";s:84:"Cazzola, M; Rogliani, P; Curradi, G; Segreti, A; Ciaprini, C; Pezzuto, G; Saltini, C";s:9:"metadata7";s:26:"10.1016/j.pupt.2009.05.005";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:220;a:14:{s:9:"citazione";s:314:"Cazzola, M., Santus, P., D'Adda, A., Pizzolato, S., Di Marco, F., & Centanni, S. (2009). Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 22(3), 177-182 [10.1016/j.pupt.2008.10.010].";s:4:"data";s:4:"2009";s:2:"id";s:18:"PUBBLICAZIONE_7903";s:6:"handle";s:10:"2108/42129";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:140:"Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD";s:9:"metadata6";s:72:"Cazzola, M; Santus, P; D'Adda, A; Pizzolato, S; Di Marco, F; Centanni, S";s:9:"metadata7";s:26:"10.1016/j.pupt.2008.10.010";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:221;a:14:{s:9:"citazione";s:236:"Comandini, A., Rogliani, P., Nunziata, A., Cazzola, M., Curradi, G., & Saltini, C. (2009). Biomarkers of lung damage associated with tobacco smoke in induced sputum. RESPIRATORY MEDICINE, 103(11), 1592-1613 [10.1016/j.rmed.2009.06.002].";s:4:"data";s:4:"2009";s:2:"id";s:20:"PUBBLICAZIONE_209429";s:6:"handle";s:10:"2108/99604";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:73:"Biomarkers of lung damage associated with tobacco smoke in induced sputum";s:9:"metadata6";s:74:"Comandini, A; Rogliani, P; Nunziata, A; Cazzola, M; Curradi, G; Saltini, C";s:9:"metadata7";s:26:"10.1016/j.rmed.2009.06.002";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:222;a:14:{s:9:"citazione";s:258:"Matera, M., Calzetta, L., Parascandolo, V., Curradi, G., Rogliani, P., & Cazzola, M. (2009). Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. PULMONARY PHARMACOLOGY & THERAPEUTICS, 22(6), 478-482.";s:4:"data";s:4:"2009";s:2:"id";s:20:"PUBBLICAZIONE_209420";s:6:"handle";s:10:"2108/99605";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:109:"Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi";s:9:"metadata6";s:76:"Matera, M; Calzetta, L; Parascandolo, V; Curradi, G; Rogliani, P; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.pupt.2009.04.005";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:223;a:14:{s:9:"citazione";s:152:"Ando F., R.P. (2008). Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD. RESPIRATORY MEDICINE, 102(6), 815-818.";s:4:"data";s:4:"2008";s:2:"id";s:19:"PUBBLICAZIONE_10137";s:6:"handle";s:10:"2108/42151";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:90:"Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD";s:9:"metadata6";s:43:"Ando F., Ruggeri P., Girbino G., Cazzola M.";s:9:"metadata7";s:26:"10.1016/j.rmed.2008.01.020";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:224;a:14:{s:9:"citazione";s:112:"Braido F., B.M. (2008). The role of Pneumococcal vaccine. PULMONARY PHARMACOLOGY & THERAPEUTICS, 21(4), 608-615.";s:4:"data";s:4:"2008";s:2:"id";s:19:"PUBBLICAZIONE_17868";s:6:"handle";s:10:"2108/42145";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:32:"The role of Pneumococcal vaccine";s:9:"metadata6";s:62:"Braido F., Bellotti M., De Maria A., Cazzola M., Canonica G.W.";s:9:"metadata7";s:26:"10.1016/j.pupt.2008.04.001";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:225;a:14:{s:9:"citazione";s:161:"Brozek J., A.E. (2008). Long-acting beta2-agonists for chronic obstructive pulmonary disease: Serious adverse events. COCHRANE DATABASE OF SYSTEMATIC REVIEWS(3).";s:4:"data";s:4:"2008";s:2:"id";s:18:"PUBBLICAZIONE_4629";s:6:"handle";s:10:"2108/42164";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:92:"Long-acting beta2-agonists for chronic obstructive pulmonary disease: Serious adverse events";s:9:"metadata6";s:121:"Brozek J., Akl E.A., Jaeschke R., Terrenato I., Cilenti V., Cazzola M., Fabbri L., O'Byrne P., Guyatt G.H., Schunemann H.";s:9:"metadata7";s:25:"10.1002/14651858.CD007200";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:226;a:14:{s:9:"citazione";s:153:"Cazzola M., B.G. (2008). Use of 6-min and 12-min walking test for assessing the efficacy of formoterol in COPD. RESPIRATORY MEDICINE, 102(10), 1425-1430.";s:4:"data";s:4:"2008";s:2:"id";s:18:"PUBBLICAZIONE_9078";s:6:"handle";s:10:"2108/42146";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:85:"Use of 6-min and 12-min walking test for assessing the efficacy of formoterol in COPD";s:9:"metadata6";s:81:"Cazzola M., Biscione G.L., Pasqua F., Crigna G., Appodia M., Cardaci V., Ferri L.";s:9:"metadata7";s:26:"10.1016/j.rmed.2008.04.017";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:227;a:14:{s:9:"citazione";s:310:"Cazzola, M. (2008). Physiologic and biological markers to assess the progression of chronic obstructive pulmonary disease [Quali parametri funzionali e biologici per la valutazione della progressione della broncopneumopatia cronica ostruttiva]. RASSEGNA DI PATOLOGIA DELL’APPARATO RESPIRATORIO, 23(1), 26-34.";s:4:"data";s:4:"2008";s:2:"id";s:18:"PUBBLICAZIONE_5018";s:6:"handle";s:10:"2108/42170";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:223:"Physiologic and biological markers to assess the progression of chronic obstructive pulmonary disease [Quali parametri funzionali e biologici per la valutazione della progressione della broncopneumopatia cronica ostruttiva]";s:9:"metadata6";s:10:"Cazzola, M";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:228;a:14:{s:9:"citazione";s:140:"Cazzola, M., & Matera, M.G. (2008). Novel long-acting bronchodilators for COPD and asthma. BRITISH JOURNAL OF PHARMACOLOGY, 155(3), 291-299.";s:4:"data";s:4:"2008";s:2:"id";s:18:"PUBBLICAZIONE_4038";s:6:"handle";s:10:"2108/42165";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:53:"Novel long-acting bronchodilators for COPD and asthma";s:9:"metadata6";s:22:"Cazzola, M; Matera, MG";s:9:"metadata7";s:20:"10.1038/bjp.2008.284";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:229;a:14:{s:9:"citazione";s:126:"Cazzola, M., & Matera, M.G. (2008). Treatment of asthma during pregnancy: more solid evidence needed. THORAX, 63(11), 944-945.";s:4:"data";s:4:"2008";s:2:"id";s:18:"PUBBLICAZIONE_4686";s:6:"handle";s:10:"2108/42171";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:64:"Treatment of asthma during pregnancy: more solid evidence needed";s:9:"metadata6";s:22:"Cazzola, M; Matera, MG";s:9:"metadata7";s:23:"10.1136/thx.2008.104463";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:230;a:14:{s:9:"citazione";s:240:"Cazzola, M., & Matera, M.G. (2008). ß-blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 178(7), 661-662 [10.1164/rccm.200806-963ED].";s:4:"data";s:4:"2008";s:2:"id";s:18:"PUBBLICAZIONE_3987";s:6:"handle";s:10:"2108/42159";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:98:"ß-blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution";s:9:"metadata6";s:22:"Cazzola, M; Matera, MG";s:9:"metadata7";s:25:"10.1164/rccm.200806-963ED";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:231;a:14:{s:9:"citazione";s:111:"Cazzola, M., Brusasco, V., & Martinez, F.J. (2008). From the authors. EUROPEAN RESPIRATORY JOURNAL, 32(2), 528.";s:4:"data";s:4:"2008";s:2:"id";s:18:"PUBBLICAZIONE_4763";s:6:"handle";s:10:"2108/42169";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:16:"From the authors";s:9:"metadata6";s:37:"Cazzola, M; Brusasco, V; Martinez, FJ";s:9:"metadata7";s:25:"10.1183/09031936.00056808";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:232;a:14:{s:9:"citazione";s:221:"Cazzola, M., Donner, C., & Hanania, N.A. (2008). One hundred years of respiratory medicine chronic obstructive pulmonary disease (COPD). Republished article. RESPIRATORY MEDICINE, 4(1), 8-25 [10.1016/j.rmedu.2007.11.019].";s:4:"data";s:4:"2008";s:2:"id";s:19:"PUBBLICAZIONE_18184";s:6:"handle";s:10:"2108/42143";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:107:"One hundred years of respiratory medicine chronic obstructive pulmonary disease (COPD). Republished article";s:9:"metadata6";s:34:"Cazzola, M; Donner, C; Hanania, NA";s:9:"metadata7";s:27:"10.1016/j.rmedu.2007.11.019";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:233;a:14:{s:9:"citazione";s:254:"Cazzola, M., Hanania, N.A., Jones, P.W., Mahler, D.A., Make, B., Ohar, J., et al. (2008). It's about time: directing our attention toward modifying the course of COPD. In Respiratory medicine (pp.37-48). London : Saunders [10.1016/S0954-6111(08)70006-4].";s:4:"data";s:4:"2008";s:2:"id";s:19:"PUBBLICAZIONE_10646";s:6:"handle";s:10:"2108/42138";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:76:"It's about time: directing our attention toward modifying the course of COPD";s:9:"metadata6";s:76:"Cazzola, M; Hanania, NA; Jones, PW; Mahler, DA; Make, B; Ohar, J; Rennard, S";s:9:"metadata7";s:29:"10.1016/S0954-6111(08)70006-4";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:234;a:14:{s:9:"citazione";s:212:"Cazzola, M., MacNee, W., Martinez, F., Rabe, K., Franciosi, L., Barnes, P., et al. (2008). Outcomes for COPD pharmacological trials: From lung function to biomarkers. EUROPEAN RESPIRATORY JOURNAL, 31(2), 416-468.";s:4:"data";s:4:"2008";s:2:"id";s:18:"PUBBLICAZIONE_5127";s:6:"handle";s:10:"2108/42156";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:74:"Outcomes for COPD pharmacological trials: From lung function to biomarkers";s:9:"metadata6";s:321:"Cazzola, M; MacNee, W; Martinez, F.J; Rabe, K.F; Franciosi, L.G; Barnes, P.J; Brusasco, V; Burge, P.S; Calverley, P.M.A; Celli, B.R; Jones, P.W; Mahler, D.A; Make,B; Miravitlles, M; Page, C.P; Palange, P; Parr, D; Pistolesi, M; Rennard, S.I; Rutten-van, Molken M.P; Stockley, R; Sullivan, S.D; Wedzicha, J.A; Wouters, E.F";s:9:"metadata7";s:28:"10.1183/​09031936.00099306";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:235;a:14:{s:9:"citazione";s:236:"Cazzola, M., Rogliani, P., & Curradi, G. (2008). Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view. RESPIRATORY MEDICINE, 102(3), 321-327 [10.1016/j.rmed.2007.11.002].";s:4:"data";s:4:"2008";s:2:"id";s:18:"PUBBLICAZIONE_4981";s:6:"handle";s:10:"2108/39859";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:118:"Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view";s:9:"metadata6";s:35:"Cazzola, M; Rogliani, P; Curradi, G";s:9:"metadata7";s:26:"10.1016/j.rmed.2007.11.002";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:236;a:14:{s:9:"citazione";s:135:"Matera M.G., C.G. (2008). Long-acting ß2 agonists in asthma and allergic rhinitis. EXPERT OPINION ON PHARMACOTHERAPY, 9(9), 1531-1539.";s:4:"data";s:4:"2008";s:2:"id";s:18:"PUBBLICAZIONE_4929";s:6:"handle";s:10:"2108/42168";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:56:"Long-acting ß2 agonists in asthma and allergic rhinitis";s:9:"metadata6";s:35:"Matera M.G., Curradi G., Cazzola M.";s:9:"metadata7";s:25:"10.1517/14656566.9.9.1531";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:237;a:14:{s:9:"citazione";s:179:"Matera, M., Calzetta, L., Sanduzzi, A., Page, C., & Cazzola, M. (2008). Effects of neuraminidase on equine isolated bronchi. PULMONARY PHARMACOLOGY & THERAPEUTICS, 21(4), 624-629.";s:4:"data";s:4:"2008";s:2:"id";s:19:"PUBBLICAZIONE_12448";s:6:"handle";s:10:"2108/42148";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:51:"Effects of neuraminidase on equine isolated bronchi";s:9:"metadata6";s:56:"Matera, M; Calzetta, L; Sanduzzi, A; Page, C; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.pupt.2008.02.003";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:238;a:14:{s:9:"citazione";s:270:"Pelaia, G., Renda, T., Gallelli, L., Vatrella, A., Busceti, M.T., Agati, S., et al. (2008). Molecular mechanisms underlying airway smooth muscle contraction and proliferation: implications for asthma. RESPIRATORY MEDICINE, 102(8), 1173-1181 [10.1016/j.rmed.2008.02.020].";s:4:"data";s:4:"2008";s:2:"id";s:18:"PUBBLICAZIONE_9105";s:6:"handle";s:10:"2108/42150";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:107:"Molecular mechanisms underlying airway smooth muscle contraction and proliferation: implications for asthma";s:9:"metadata6";s:116:"Pelaia, G; Renda, T; Gallelli, L; Vatrella, A; Busceti, MT; Agati, S; Caputi, M; Cazzola, M; Maselli, R; Marsico, SA";s:9:"metadata7";s:26:"10.1016/j.rmed.2008.02.020";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:239;a:14:{s:9:"citazione";s:149:"Cazzola M. (2007). Adequate surrogate parameters in COPD studies [Surrogatparameter bei COPD]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 132(10), 522-523.";s:4:"data";s:4:"2007";s:2:"id";s:18:"PUBBLICAZIONE_3420";s:6:"handle";s:10:"2108/42214";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:74:"Adequate surrogate parameters in COPD studies [Surrogatparameter bei COPD]";s:9:"metadata6";s:10:"Cazzola M.";s:9:"metadata7";s:21:"10.1055/s-2007-970371";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:240;a:14:{s:9:"citazione";s:85:"Cazzola M. (2007). Editorial. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 1(1), 3-4.";s:4:"data";s:4:"2007";s:2:"id";s:19:"PUBBLICAZIONE_20742";s:6:"handle";s:10:"2108/42217";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:9:"Editorial";s:9:"metadata6";s:10:"Cazzola M.";s:9:"metadata7";s:24:"10.1177/1753465807081457";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:241;a:14:{s:9:"citazione";s:278:"Cazzola M., A.F. (2007). A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 20(5), 556-561 [10.1016/j.pupt.2006.06.001].";s:4:"data";s:4:"2007";s:2:"id";s:19:"PUBBLICAZIONE_16973";s:6:"handle";s:10:"2108/42212";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:168:"A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD";s:9:"metadata6";s:80:"Cazzola M., Ando F., Santus P., Ruggeri P., Di Marco F., Sanduzzi A., D'Amato M.";s:9:"metadata7";s:26:"10.1016/j.pupt.2006.06.001";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:242;a:14:{s:9:"citazione";s:137:"Cazzola M., C.G. (2007). How to prevent relapse after acute exacerbation of asthma?. POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 117, 487-490.";s:4:"data";s:4:"2007";s:2:"id";s:18:"PUBBLICAZIONE_3866";s:6:"handle";s:10:"2108/39856";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:58:"How to prevent relapse after acute exacerbation of asthma?";s:9:"metadata6";s:22:"Cazzola M., Curradi G.";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:243;a:14:{s:9:"citazione";s:145:"Cazzola M., M.M. (2007). Safety of long-acting ß2-agonists in the treatment of asthma. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 1(1), 35-46.";s:4:"data";s:4:"2007";s:2:"id";s:18:"PUBBLICAZIONE_3844";s:6:"handle";s:10:"2108/42215";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:61:"Safety of long-acting ß2-agonists in the treatment of asthma";s:9:"metadata6";s:23:"Cazzola M., Matera M.G.";s:9:"metadata7";s:24:"10.1177/1753465807081747";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:244;a:14:{s:9:"citazione";s:187:"Cazzola, M., & Matera, M.G. (2007). The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: A pilot study. RESPIRATORY MEDICINE, 101(5), 957-962.";s:4:"data";s:4:"2007";s:2:"id";s:18:"PUBBLICAZIONE_8368";s:6:"handle";s:10:"2108/42208";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:111:"The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: A pilot study";s:9:"metadata6";s:22:"Cazzola, M; Matera, MG";s:9:"metadata7";s:26:"10.1016/j.rmed.2006.09.012";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:245;a:14:{s:9:"citazione";s:187:"Cazzola, M., Donner, C.F., & Hanania, N.A. (2007). One hundred years of chronic obstructive pulmonary disease (COPD). RESPIRATORY MEDICINE, 101(6), 1049-1065 [10.1016/j.rmed.2007.01.015].";s:4:"data";s:4:"2007";s:2:"id";s:19:"PUBBLICAZIONE_22018";s:6:"handle";s:10:"2108/42216";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:65:"One hundred years of chronic obstructive pulmonary disease (COPD)";s:9:"metadata6";s:35:"Cazzola, M; Donner, CF; Hanania, NA";s:9:"metadata7";s:26:"10.1016/j.rmed.2007.01.015";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:246;a:14:{s:9:"citazione";s:147:"Cazzola, M., Matera, M.G., Rogliani, P., & Page, C. (2007). Treating systemic effects of COPD. TRENDS IN PHARMACOLOGICAL SCIENCES, 28(10), 544-550.";s:4:"data";s:4:"2007";s:2:"id";s:18:"PUBBLICAZIONE_3552";s:6:"handle";s:10:"2108/42211";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:33:"Treating systemic effects of COPD";s:9:"metadata6";s:44:"Cazzola, M; Matera, MG; Rogliani, P; Page, C";s:9:"metadata7";s:26:"10.1016/j.tips.2007.09.006";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:247;a:14:{s:9:"citazione";s:196:"Matera, M.G., & Cazzola, M. (2007). Ultra-long-acting beta(2)-adrenoceptor agonists - An emerging therapeutic option for asthma and COPD?. DRUGS, 67(4), 503-515 [10.2165/00003495-200767040-00002].";s:4:"data";s:4:"2007";s:2:"id";s:19:"PUBBLICAZIONE_20977";s:6:"handle";s:10:"2108/42207";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:101:"Ultra-long-acting beta(2)-adrenoceptor agonists - An emerging therapeutic option for asthma and COPD?";s:9:"metadata6";s:22:"Matera, MG; Cazzola, M";s:9:"metadata7";s:32:"10.2165/00003495-200767040-00002";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:248;a:14:{s:9:"citazione";s:151:"Raimondi G., C.S. (2007). Autonomic nervous system dysfunction in the course of active pulmonary tuberculosis. RESPIRATORY MEDICINE, 101(8), 1804-1808.";s:4:"data";s:4:"2007";s:2:"id";s:19:"PUBBLICAZIONE_18223";s:6:"handle";s:10:"2108/42210";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:83:"Autonomic nervous system dysfunction in the course of active pulmonary tuberculosis";s:9:"metadata6";s:104:"Raimondi G., Contini S., Maria Legramante J., Bocchino M., Sacco S., Pallante M., Cazzola M., Saltini C.";s:9:"metadata7";s:26:"10.1016/j.rmed.2007.02.008";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:249;a:14:{s:9:"citazione";s:277:"Santus, P., Centanni, S., Morelli, N., Di Marco, F., Verga, M., & Cazzola, M. (2007). Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting beta(2)-agonists. RESPIRATORY MEDICINE, 101(8), 1798-1803 [10.1016/j.rmed.2007.02.007].";s:4:"data";s:4:"2007";s:2:"id";s:19:"PUBBLICAZIONE_19909";s:6:"handle";s:10:"2108/42209";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:120:"Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting beta(2)-agonists";s:9:"metadata6";s:69:"Santus, P; Centanni, S; Morelli, N; Di Marco, F; Verga, M; Cazzola, M";s:9:"metadata7";s:26:"10.1016/j.rmed.2007.02.007";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:250;a:14:{s:9:"citazione";s:275:"Vatrella, A., Bocchino, M., Perna, F., Scarpa, R., Galati, D., Spina, S., et al. (2007). Induced sputum as a tool for early detection of airway inflammation in connective diseases-related lung involvement. RESPIRATORY MEDICINE, 101(7), 1383-1389 [10.1016/j.rmed.2007.02.003].";s:4:"data";s:4:"2007";s:2:"id";s:19:"PUBBLICAZIONE_14655";s:6:"handle";s:10:"2108/42213";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:115:"Induced sputum as a tool for early detection of airway inflammation in connective diseases-related lung involvement";s:9:"metadata6";s:102:"Vatrella, A; Bocchino, M; Perna, F; Scarpa, R; Galati, D; Spina, S; Pelaia, G; Cazzola, M; Sanduzzi, A";s:9:"metadata7";s:26:"10.1016/j.rmed.2007.02.003";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:251;a:14:{s:9:"citazione";s:151:"Cazzola M., M.M. (2006). The effective treatment of COPD: Anticholinergics and what else?. DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES, 3(3), 277-286.";s:4:"data";s:4:"2006";s:2:"id";s:18:"PUBBLICAZIONE_3201";s:6:"handle";s:10:"2108/40928";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:64:"The effective treatment of COPD: Anticholinergics and what else?";s:9:"metadata6";s:23:"Cazzola M., Matera M.G.";s:9:"metadata7";s:27:"10.1016/j.ddstr.2006.09.009";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:252;a:14:{s:9:"citazione";s:107:"Cazzola M., M.M. (2005). Inflammation - A new therapeutic target in pneumonia. RESPIRATION, 72(2), 117-126.";s:4:"data";s:4:"2005";s:2:"id";s:19:"PUBBLICAZIONE_22101";s:6:"handle";s:10:"2108/39950";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:52:"Inflammation - A new therapeutic target in pneumonia";s:9:"metadata6";s:35:"Cazzola M., Matera M.G., Pezzuto G.";s:9:"metadata7";s:17:"10.1159/000084039";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:253;a:14:{s:9:"citazione";s:146:"Cazzola M., S.C. (2005). Novel approaches to the treatment of bacterial lower respiratory tract infections: Introduction. RESPIRATION, 72(1), 7-8.";s:4:"data";s:4:"2005";s:2:"id";s:18:"PUBBLICAZIONE_4279";s:6:"handle";s:10:"2108/39986";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:52:"Settore MED/10 - Malattie dell'Apparato Respiratorio";s:9:"metadata4";N;s:9:"metadata5";s:95:"Novel approaches to the treatment of bacterial lower respiratory tract infections: Introduction";s:9:"metadata6";s:22:"Cazzola M., Saltini C.";s:9:"metadata7";s:17:"10.1159/000083393";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}}" } ["meta_keywords"]=> array(1) { [0]=> string(1) "," } ["reserved"]=> array(1) { [0]=> string(1) "0" } ["auth_ip"]=> array(1) { [0]=> string(1) "0" } } ["_fieldBoosts":protected]=> array(6) { ["content_id"]=> bool(false) ["content_title"]=> bool(false) ["description"]=> bool(false) ["meta_keywords"]=> bool(false) ["reserved"]=> bool(false) ["auth_ip"]=> bool(false) } } }